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Abstract 
Background and objective: ALT and SLT are both safe and effective for 
glaucoma treatment. We performed a cost-effectiveness analysis (CEA) of SLT 
versus ALT for a six-month follow-up period in uncontrolled open angle 
glaucoma patients having at least one full previous SLT from an ongoing RCT. 
Methods: Trial based treatment costing and IOP reduction at 6-month follow-up 
from baseline for both intervention arms were calculated. A decision tree model 
was developed considering possible clinical pathways of patients undergoing 
repeat laser trabeculoplasty. CEA among ALT and SLT was done, and ICERs 
were calculated from both societal and ministry perspective. One way sensitivity 
analysis was done for cost and effectiveness parameters. Results: From Societal 
perspective, expected cost/effectiveness for ALT and SLT was $458/0.143 mmHg 
vs $448/0.123 mmHg respectively and from ministry perspective, $467/0.154 
mmHg vs $446/0.122 mmHg, respectively. To switch from SLT to ALT, it would 
cost $ 356.49 for each extra unit IOP reduction from societal perspective and from 
ministry perspective, the same would cost $ 649.71. This ICERs were much higher 
in comparison to ICERS of other IOP lowering medications in similar situations. 
Conclusion: Neither ALT nor SLT strategies were clearly dominated by any 
other. ALT is slightly more effective and slightly costly over SLT. Sensitivity 
analysis with effectiveness variables showed dominance of SLT over ALT for 
some instances. SLT has the theoretical plausibility of repeatability and is also 
easier to perform than ALT. All these factors should be considered when opting 
between ALT and SLT strategies.  
KEYWORDS:   
Argon laser trabeculoplasty, cost-effectiveness analysis, decision model tree, 
economic evaluation, glaucoma, incremental cost effectiveness ratio, intra-ocular 
pressure, selective laser trabeculoplasty. 
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Chapter 1 - Introduction 
Glaucoma, a progressive degeneration of the retinal ganglion cells, results in 
characteristic visual field defects (initially peripheral, then central loss of field of 
vision) (Gemenetzi et al. 2011). It may remain asymptomatic until becoming 
severe because of redundancy in the sensory system and the binocular nature of 
vision; one eye may compensate for early losses in the other (Weinreb et al. 2014). 
It is the second-leading  cause of blindness and leading cause of irreversible 
blindness worldwide, having an estimation of 79.6 million glaucoma patients by 
2020, and 74% of these will have open angle glaucoma (OAG) (Quigley et al. 
2006). By 2040, an estimated 111.8 million people will suffer from glaucoma 
worldwide (Tham et al. 2014). Primary OAG (POAG) is the most common type; 
others include pigmentary OAG and pseudoexfoliative OAG (Musch et al. 2012). 
Increased intra ocular pressure (IOP) is considered as the most important 
modifiable factor for development and prognosis of POAG (Anderson et al. 1989). 
But the disease may occur in normal IOP also (Bahrami et al. 2006). Other 
important risk factors are thinner central corneal measurement, older age, and 
family history for glaucoma (Coleman et al. 2008, Friedman et al. 2004). 
Along with age-related macular degeneration and diabetic retinopathy, glaucoma 
is the most important ocular public health problem in Canada with an annual 
economic burden close to $500 million (Hodge et al. 2004).  It affects 1-2% of 
individuals over age 50. An estimated 400,000 Canadians are affected with over 
10,000 blind (Hodge et al. 2004, Tielsh et al. 1991). ). In 2008-2009, Statistics 
Canada reported that, more than 450,000 Canadians aged 45 years and above have 
been diagnosed with glaucoma by health professionals (Statistics Canada, 2010).  
The quick accrual of medical information and rapidly evolving newer medical 
technologies results in several different management options even for a single 
medical condition. Thus, selection of treatment modalities becomes difficult at 
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both individual and policy level, warranting the development of guidelines for 
clinical practice and to set pragmatic funding priorities for policy on medical 
intervention directing what action should be done and paid for (Petitti. 2000). 
Expensive health care, globally, includes a large and increasing share of private 
and public expenditure (CIHI 2013). Economic considerations for treatment 
options are getting more importance day by day as health systems are under 
enormous pressure to maximize the value for money. Consequently, clinical 
effectiveness alone is not the only criteria for adoption of an intervention 
nowadays. The value for money has to be considered equally along with the 
clinical effectiveness (Health Council of Canada. 2009). Economic evaluation 
measures and values explicitly to compare alternative courses of action in terms of 
both their costs and good or bad consequences. (Drummond et al. 2015; Hurley. 
2010). Cost-Effectiveness Analysis (CEA), a method for economic evaluation, 
compares decision options in terms of their monetary costs and offers a framework 
where clinical effectiveness data along with costs are examined together and 
relevant issues on costs and clinical effectiveness of comparative alternative 
medical interventions can be addressed. A decision analytic model, especially in 
medical applications, is the usual conceptual basis for analysis of the effectiveness 
of the decision options. CEA, in addition, involves cost identification of the 
decision options and their valuation. In many instances, CEA also explores 
preferences of society or individuals of the decision option for the health outcomes 
(Petitti, 2000), termed utilities. The Incremental Cost-Effectiveness Ratio or 
ICER, which is the difference in cost divided by the difference in effectiveness of 
two or more competitive or alternative programs or interventions, represents the 
cost per additional unit of health effect (Petitti, 2000). Considering local context 
and decision rules, decision makers may use the ICER to determine whether or not 
a technology represents a good value for money. 
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Open angle glaucoma has a life-long progressive course. Once started, it is non-
curable, only treatable. Its management requires careful selection of different 
combination of treatment modalities (mainly medications, laser therapy and 
surgery) on an individual patient at different time point and situation to achieve 
and maintain the target IOP to either halt or delay the disease progression. 
Otherwise, it may result in negative health consequences like increased blindness, 
falls, depression, and decrease in quality of life (Schmier et al. 2007). The 
mainstay of treating glaucoma is to halt or delay the deterioration of glaucomatous 
visual field defects, typically by reducing intraocular pressure.  
Pharmacological treatment to lower increased IOP started nearly 150 years ago 
(Realini, et al. 2011). Currently, there are five major classes of drugs for the 
treatment of glaucoma: (i) Prostaglandin analogues (PGAs)  ; (ii) Beta-
adrenoceptor antagonists; (iii) Adrenoceptor agonists; (iv) Carbonic anhydrase 
inhibitors (CAIs); and (v) Cholinergics (acetylcholine receptor agonists) (Marquis 
and Whitson.2005), with at least 56,000 possible options for medication types, 
doses and schedules of glaucoma (Realini and Fetchner, 2002). They act by either 
decreasing aqueous humor production or by increasing aqueous outflow. 
Additional treatment modalities include stents, non-incisional surgery and 
incipient neuro-protective treatment (Wentz et al. 2014). A new emerging future 
treatment option for glaucoma is Rho kinase inhibitor (RKI), which inhibits the 
Rho-associated protein kinase (ROCK) signaling pathway (Bagnis et al.2011; 
Wang and Chang. 2014). Unfortunately, not all patients reach intra ocular pressure 
goals, despite efforts to treat with either medical monotherapy or combination of 
medical therapies. Use of anti-glaucomatous medications also carries the risk of 
ocular and systemic adverse effects. Non- compliance with instilling ocular 
medications on a regular basis is also a great barrier to the success of 
pharmacological therapy (Rotchford et al. 1998). Despite the government’s 
funding for glaucoma medications for those aged 65 and over in Canada, the non-
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adherence and non-compliance issues related to glaucoma medications remain a 
great challenge for optimal successful outcome of medical treatment (Kholdebarin 
et al. 2008). 
Surgical therapy may be effective but carries the risk of sight threatening 
hemorrhage, infection, or hypotony (Vijaya et al. 2011).  
Laser treatment of glaucoma guarantees patient compliance without any disastrous 
post-procedural complications. The results of Glaucoma Laser Trial (GLT) 
demonstrated that, laser trabeculoplasty (LTP) was at least as efficacious as anti-
glaucomatous medications as the first-line treatment for POAG patients (The 
Glaucoma Laser Trial Research Group, 1990; The Glaucoma Laser Trial Research 
Group, 1995). Argon laser trabeculoplasty (ALT), introduced by Wise and Witter 
in 1979, is an effective way of lowering increased IOP by facilitating aqueous 
outflow through trabecular meshwork (TM) (Wise et al. 1979), but its 
effectiveness decreases with retreatment due to detrimental disruption to the 
microstructure of the TM, and this excessive TM damage often determines 
treatment failure (Hodge et al. 2005; Fink et al. 1988). In 1995, Latina introduced 
selective laser trabeculoplasty (SLT), an alternative laser treatment, by using a 
frequency doubled, Q switched Nd: YAG laser (532 nm) in lieu of an argon wave 
length (488 nm to 514 nm)   (Latina et al. 1995, Latina et al. 1998). SLT targets 
the pigmented TM keeping the TM architecture more preserved, especially the 
long spacing collagen (Cvenkel et al.2003). This has the theoretical advantage of 
successful repeatability of SLT over ALT. The efficacy and safety of SLT are 
similar to ALT for first laser treatments (Damji et al. 1999; Hodge et al. 2005, 
Damji et al. 2006).  
The outcome of glaucoma treatments, especially in terms of IOP lowering effects, 
varies widely from patient to patient. Medications have non-compliance issues and 
surgical options are tagged with complications, often sight and even life 
threatening. Laser treatments, are devoid of these drawbacks and are now used 
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widely with increasing popularity among patients and ophthalmologists. Laser 
treatments, especially SLT, are even considered by many ophthalmologists as a 
good choice for first-line treatment as studies support this claim (Waisbourd and 
Katz, 2014). SLT has the theoretical advantage for repeat treatment of glaucoma 
over ALT.  
The aim of this thesis is to perform a cost-effectiveness analysis of SLT versus 
ALT in uncontrolled open angle glaucoma patients (including ocular hypertension, 
pigmentary dispersion syndrome and pseudoexfoliation syndrome) and at least one 
previous full SLT by examining the relevant data from an ongoing randomized 
clinical trial entitled ‘A randomized clinical trial of selective laser trabeculoplasty 
(SLT) in open angle glaucoma who had been previously treated with complete 
SLT’ on a short horizon (6-month) of follow-up. It will provide us important 
information and direction about the cost-effectiveness of ALT and SLT treatment 
for above-mentioned group of patients. We will also have a general impression of 
both cost and effectiveness (in term of IOP lowering effect) of ALT and SLT in a 
usual setting of such health care practice. 
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Chapter 2 - Background and Literature Review  
2.1- Glaucoma: An overview 
2.1.1 The sneak thief of vision 
Glaucoma, a collective term for heterogeneous group of conditions having, in 
common, an irreversible, progressive optic neuropathy with distinctive patterns of 
structural changes in the optic nerve head (cupping) resulting in visual field loss 
(Rouland et al, 2005). The diversities of clinico-histopathological manifestations 
are not commonly appreciated by the general people (Allingham et al. 2011). The 
initial slow impairment of vision of the affected eye, starting usually in the 
peripheral field of vision and encroaches centrally in advance stage, is well 
compensated by the fellow healthy eye (Weinreb et al. 2014). As a result, when 
patient recognizes the visual field defect, progression of glaucoma usually causes 
severe and irreversible damage to the retinal ganglionic cell and visual field in the 
affected eye (Pan and Varma, 2011).  
2.1.2 Historical Background  
The description of glaucomatous condition can be found during the era of 
Hippocrates (Sorsby. 1932).  The term ‘Glaucoma’ coined from the early Greek 
‘glaukos’, a term to describe blue, green or light gray and possibly also used to 
indicate the color of the pupil in affected eyes (Leffler et al. 2015; Mark, 2010). 
Until 17th century, glaucoma was nearly indistinguishable from cataract and 
inflammatory condition of the eye (Frezzotti, 2000). After introduction of 
ophthalmoscope in 1851 by Hermann Vonn Helmholtz (Keeler, 2002), 
ophthalmologists could observe that excavated optic neuropathy was characteristic 
of patients having co-morbidity with mydriasis, an anteriorly prominent lens and a 
green pupil (glaucoma), albeit some patient with normal pupil (amaurosis) also 
had excavated optic neuropathy (Leffler et al. 2015). In the middle of the 19th 
century, Graefe thought ocular hypertension as a form of glaucoma.  Donders 
called it “glaucoma simplex” shortly thereafter. Mackenzie, Jaeger, Weber and 
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Graefe emphasized that, the cupping viewed during ophthalmoscopic examination 
was due to the swelling of optic disc resulted from elevated aqueous pressure 
(Nathan, 2000; Frezzotti, 2000). The ciliary body as a source of aqueous humor 
secretion was discovered by Leber (Barnshaw, 1979). Graefe developed a 
transpalpebral tonometer in 1862, and Maklakoff and Fick developed applanation 
tonometers in 1880 (Kniestedt et al. 2008), both intended to measure intraocular 
pressure, a cornerstone diagnostic aspect of the disease.  
2.1.3 Classification 
Glaucoma is usually classified based on: 
 Etiological* 
 Primary (No identifiable ocular or systemic disorders) 
 Secondary (Identifiable ocular or systemic disorders) 
 Mechanism of IOP elevation* 
 Open angle (No clinically visible anatomical obstruction to aqueous 
outflow in   the iridocorneal drainage angle) with IOP elevation or 
without IOP elevation (Normal tension). 
 Angle closure (Clinically visible anatomical obstruction to aqueous 
outflow in the iridocorneal drainage angle) 
 Based on severity* 
 Early glaucoma 
 Moderate glaucoma 
 Advanced glaucoma 
 Developmental** 
 Primary congenital glaucoma (from birth to 9 years) 
 Primary juvenile glaucoma (from 9 years to 35 years) 
 Axenfeld and Rieger anomaly (AXRA) 
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 Peters anomaly 
 Anirida 
*(Barton and Hitchings, 2013a); **(Auw-Haedrich et al. 2015). 
2.1.3.1 Ocular Hypertension (OH) 
In 1970, the term ‘Ocular Hypertension’ was introduced to separate persons 
having IOP greater than 21 mm Hg, who are at increased risk of developing 
POAG than persons with normal IOP (i.e., <21 mm Hg) (Allingham et al. 2011). 
Despite the similar flow pattern of aqueous humor of a person with normal IOP, 
patients with ocular hypertension exhibit higher IOP and resistance to aqueous 
outflow (Ziai et al. 1993).  
2.1.3.2 Primary Open Angle Glaucoma (POAG) 
It is the most prevalent form of glaucoma (aka Chronic Open-Angle Glaucoma). 
Damage of the optic nerve head is the ultimate result of the disease pathway due to 
all potential etiologies. As stated earlier, it has no warning signs until the 
development of advanced visual field loss. Elevated IOP (usually>21mm Hg 
before the start of treatment), due to aqueous outflow obstruction, is the most 
important modifiable risk factor (Allingham et al. 2011). When the pathway of 
aqueous humor is blocked, pressure inside eyeball raises due to excess 
accumulation of aqueous humor.  This increased pressure causes slow and 
irreversible damage of optic nerve head leading to irreversible blindness. 
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Figure 1: Different parts of eye 
 [Source: 
https://commons.wikimedia.org/wiki/File:Three_Main_Layers_of_the_Eye.png] 
            
Transforming growth factor - β2 (TGF- β2), the predominant isoform of 
transforming growth factor - β in ocular tissue, is elevated in POAG patients than 
normal individuals.  It may decrease the cellularity of the trabecular meshwork 
resulting in excessive amounts of extracellular matrix materials and formation of 
plaque from the thickened sheath of elastic fibers with eventual increased 
resistance to the aqueous outflow (Tamm and Fuchshofer, 2007; Agarwal et al. 
2015). Narrowing of Schlemm’s canal with collapse also results in increased 
resistance to the aqueous outflow (Johnson 2010). Attenuation of intrascleral 
10 
 
channels may also contribute to increased aqueous outflow resistance (Grieshaber 
et al. 2010). Many patients with POAG are unusually sensitive to corticosteroids 
that may also aggravate the situation (Allingham et al. 2011). Along with elevated 
IOP, additional factors like induction of fibrosis and capillary loss (with increased 
connective tissue in the septa and surrounding the central retinal vessels, including 
increased amounts of type IV and VI collagen) are involved in glaucomatous optic 
neuropathy (Gottanka et al. 2005). Low cerebrospinal fluid (CSF) pressure is often 
observed in POAG (Berdahl et al. 2008).  The critical balance between 
neuroprotective and neurodegenerative roles of the immune system in glaucoma 
determines the ultimate fate of retinal ganglionic cells in response to various 
stressors (Allingham et al. 2011). In experimental glaucoma, apoptotic death of 
retinal ganglionic cells occurrs (Quigley, 1999). The Canadian Glaucoma Study 
reported an association of elevated anticardiolipin antibody (one of the 
antiphospholipid antibodies), with progression of POAG (Chauhan et al. 2008). In 
treatment of a patient with POAG, the target IOP range for both eyes in which 
there will presumably be no further optic nerve damage, has to be determined and 
would need to be reevaluated at each follow-up visit. Usually, target IOP is 
achieved with topical anti-glaucomatous medications. If not achieved despite 
maximum tolerated medical therapy, laser trabeculoplasty (argon or selective) is 
indicated followed by glaucoma filtration surgery or other appropriate incisional 
surgical therapeutic maneuvers (Allingham et al. 2011). 
2.1.3.3 Pseudoexfoliation Syndrome (PXFS) and Pseudoexfoliative Glaucoma 
(PXFG) 
A systemic disorder with important eye manifestations, pseudoexfoliation 
syndrome (aka exfoliation syndrome) is globally the most common identifiable 
cause (secondary) of open angle glaucoma; it is also associated with angle closure 
glaucoma and cataract with zonular instability (Ritch, 1994). When glaucoma is 
present with PXFS, it is called pseudoexfoliative glaucoma (aka exfoliative 
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glaucoma, capsular glaucoma). Due to rarity of true lens capsule delamination, the 
term ‘pseudo’ is most often used (Allingham et al. 2011). PXFS is more common 
in older age groups (Aström et al. 2007). Most eyes with PXFG follow an open 
angle mechanism, (a small number present with acute angle closure glaucoma), 
and control of IOP is difficult in open angle PXFG compared to similar IOP level 
of POAG (Allingham et al. 2011).  When PXFS is fully developed, exfoliation 
material is seen on the anterior lens surface, and increased and uneven trabecular 
meshwork pigmentation due to excessive pigment dispersion is observed. In 
PXFG, elevated IOP and typical glaucomatous neuroretinal rim loss are present 
along with exfoliation material in the anterior lens surface and on the corneal 
endothelium and also on the pupillary margin of the iris (Allingham et al. 2011; 
Ritch and Schlötzer-Schrehardt, 2001). In PXFG, there is greater diurnal IOP 
fluctuation and treatment is challenging. Regarded as an inherited 
microfibrilopathy, development of PXFS and PXFG are strongly associated with 
polymorphism of lysyl oxidase-like protein 1 (LOXL1) gene, a member of a gene 
family that plays an important role in elastin metabolism (Allingham et al. 2011). 
2.1.3.4 Pigment Dispersion Syndrome (PDS) and Pigmentary Glaucoma (PG) 
These are two consecutive stages of the same disease process marked by 
disruption of the iris pigment epithelium and deposition of the dispersed pigment 
granules throughout the anterior segment.  A concave iris contour allowing 
apposition of its posterior surface to the zonular bundles is responsible for PDS. 
Disruption of the iris pigment epithelium also releases pigment granules into the 
aqueous humor. The classic diagnostic triad are corneal endothelial pigmentation 
(Krukenberg spindle), slit-like, radial, mid-peripheral iris transillumination 
defects, and dense homogeneous pigmentation of the trabecular meshwork. 
Patients with PDS are usually myopic, so incidental diagnosis of PDS is often 
made at an early stage. Young males are at greater risk of developing PDS. It may 
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take years to develop PG from PDS and once established, PG is difficult to 
control. PXFS may be more common in PG (Tello et al. 2010). 
2.1.3.5 Angle Closure Glaucoma (ACG) 
Angle closure results from apposition of the peripheral iris to the trabecular 
meshwork leading to obstruction of aqueous outflow (Allingham et al. 2011). This 
results in a sudden (acute) or gradual (chronic) increase in intraocular pressure 
(Cyrlin, 2010). Two mechanisms of ACG are described as follows (Allingham et 
al. 2011): 
 The Anterior Mechanism: The peripheral iris is pulled into the iridocorneal 
angle by contraction of an abnormal tissue (i.e., fibrovascular membrane, 
endothelial layer with a Descemet-like membrane, inflammatory 
precipitates) that bridges the anterior chamber angle. 
 The Posterior Mechanism: Peripheral iris is pushed into the anterior 
chamber angle due to pressure behind the iris, lens, or vitreous, with or 
without pupillary block (see below). Posterior mechanism with pupillary 
block causes pupillary block glaucoma.  
 Primary angle closure glaucoma (PACG), most common variety of ACG, will 
have an estimated 21 million cases globally by 2020 (Quigley and Broman, 2006). 
Most cases of PACG are due to pupillary block, the most frequent cause of angle 
closure glaucoma (Nolan et al. 2000; Gazzard et al. 2003). Flow through the pupil 
is compromised and the peripheral iris bows forward against the trabecular 
meshwork. Increased pressure gradient between the posterior and anterior chamber 
eventually blocks the outflow. The symptoms of acute angle closure glaucoma are 
sudden and severe, with marked pain, blurred vision, elevated IOP, nausea and 
vomiting, minimal cell or flare, and a fixed or sluggish mid-dilated or irregular 
pupil. The initial treatment for an acute attack is to lower the IOP and relieve the 
pupillary block in the affected eye, including emergency paracentesis. In chronic 
angle closure glaucoma, the angle gradually narrows without precipitating an 
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acute attack and over time, a portion of the anterior chamber is permanently closed 
by peripheral anterior synechiae (scar tissue). Their corneas are usually clear and 
non-edematous, but may have more extensive optic disc and field of vision 
damage. These patients should be treated in a similar way as POAG (Allingham et 
al. 2011; Cyrlin, 2010). 
2.1.4 Pathophysiology 
The underlying pathophysiology of glaucoma is not yet fully understood. 
However, aqueous humor dynamics, optic nerve alterations and loss of visual 
functions are so far identified as key events for development of glaucoma. As 
already discussed, vascular, immunologic and cell signaling mechanisms may be 
involved. 
2.1.4.1 Aqueous Humor Dynamics and IOP 
Aqueous humor, a clear ultrafiltration fluid of plasma, fills and helps to form the 
anterior and posterior chambers of the eye. The ciliary body (site of aqueous 
humor production) and the trabecular meshwork and uveoscleral pathway (the 
principal site of aqueous humor outflow) are the main ocular structures related to 
aqueous humor dynamics (Goel et al. 2010). Aqueous leaves the eye through both 
conventional and unconventional pathways. The conventional or trabecular 
outflow pathway refers to exit of aqueous humor at the anterior chamber angle 
through trabecular meshwork, the Schlemm canal, intrascleral channels, episcleral 
and conjunctival veins. In the unconventional or uveoscleral pathway, it exits by 
passing through the suprachoroidal - scleral tissues. IOP is a function of the 
balance of aqueous humor inflow and outflow. A steady IOP is the result of equal 
inflow and outflow of aqueous humor (Allingham et al. 2011). 
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Figure 2: Outflow of aqueous humor 
                                       
2.1.4.2 Glaucomatous Optic Nerve Damage  
The optic nerve head is the distal portion of the optic nerve (2nd Cranial nerve). It 
encompasses the nerve fibers from the ganglionic cell layer of the retina and 
converges upon the nerve head into the fundus. The optic nerve head is directly 
susceptible to IOP elevations. The central area of depression in the optic head is 
known as the cup. The tissue between the cup and the disc margin is the neural 
rim, where the bulk of the axons are located. The nerve head may be arbitrarily 
divided into four portions from anterior to posterior:  
• Surface nerve fiber layer: It is the innermost part composed mainly of nerve 
fibers. 
• Prelaminar region: It is the anterior portion of the lamina cribrosa with 
predominance of nerve axons and astrocytes. Astrocytes are glial cells which 
provide a continuous layer between the nerve fibers and blood vessels in the optic 
nerve head. 
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• Lamina cribrosa region: It contains fenestrated sheet of scleral connective 
tissue and occasional elastic fibers. The sheets are separated from the fenestrae by 
the lining of astrocytes. 
• Retrolaminar region: This area has less astrocytes and characterized by 
acquisition of myelin supplied by oligodendrocytes. 
 
 
Figure 3: Optic nerve anatomy 
 
Glaucomatous optic nerve damage involves progressive asymmetric loss 
(thinning) of neural rim tissue (manifested by an enlargement in the area of 
cupping and pallor), disc hemorrhages and peripapillary nerve fiber bundle 
damage that can be revealed by careful office examination and photographic 
documentation. Computed image analysis and blood-flow measures may provide 
more precise information. Cup to disc ratio (CDR) is only one of the measures of 
the amount of neural tissue in the optic nerve with Optical coherence tomography 
(OCT), now also an important part of the optic nerve assessment. (Allingham et al. 
2011).  
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2.1.4.3 Visual Field Defect in Glaucoma  
The normal boundary of field of vision is approximately 60 degrees above and 
nasal, 70 to 75 degrees below and 100 to 110 degrees temporal to fixation 
(Allingham et al. 2011). In early glaucoma, peripheral field defects, usually a nasal 
step, may be the only abnormality detected with perimetry (Caprioli and Spaeth, 
1985). In advance stage central vision is also compromised. Some of the other 
visual field defects associated with glaucoma include temporal wedge, arcuate 
defects, - concentric contraction, and enlargement of the blind spot. Automated or 
manual perimetry can be used to measure visual field (Allingham et al. 2011).  
 
Figure 4: Normal boundary of field of vision 
                                                
2.1.5 Natural History of Glaucoma 
The natural history of glaucoma, in general, can be divided into five stages 
(Allingham et al. 2011): 
 Stage 1- Initiating events: The series of conditions that initiate the chain of 
events responsible for favoring the onset of any pathologic or physiologic 
alterations pertinent to optic nerve function or aqueous humor dynamics. 
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 Stage 2 - Structural alterations: Changes in tissues that may ultimately lead 
to alterations in optic nerve function or aqueous humor dynamics. 
 Stage 3 - Functional alterations: Physiologic abnormalities leading directly 
or indirectly to optic nerve damage. 
 Stage 4 - Retinal ganglionic cell and optic nerve damage: Loss of retinal 
ganglionic cells and their associated axons. 
 Stage 5 - Visual loss: Progressive loss of vision due to progressive optic 
nerve damage. 
2.1.5.1 Natural History of POAG 
The detection of slowly progressive POAG is delayed until in its advance stage 
due to lack of symptoms. The progression rate of visual defects and response to 
treatment to delay or halt the visual field damage is not uniform across all patients 
(Leske et al. 2004). Considering the clinical care of POAG, the natural history can 
be divided chronologically into following three phases (Allingham et al. 2011): 
 The Latency Phase: It starts with the glaucomatous optic nerve damage 
extending up to the detection threshold, at which point the optic nerve 
damage can be accurately detected by the diagnostic procedure.  
 Detectable Preclinical Phase: This is the lengthy asymptomatic phase 
during which, glaucoma can be detected with a diagnostic procedure. This 
phase continues until appearance of symptoms. However, detection of optic 
nerve damage in a single visit is often difficult. 
 Clinical Phase: It is marked by the onset of symptoms, usually when the 
disease is advanced. It may take decades to reach this phase. 
2.1.5.2 Natural History of ACG 
ACG can be acute, sub-acute and chronic that can occur in same person at 
different time period and progression of ACG can be divided into following three 
stages (Pan and Verma, 2011): 
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 Anatomically narrow angle without elevated IOP, abnormal visual fields or 
peripheral anterior synechiae. 
 Development of peripheral anterior synechiae or a closed angle with 
elevated IOP. 
 Development of glaucomatous optic neuropathy and visual field changes 
along with an anatomical angle closure. 
2.1.6 Descriptive Epidemiology 
Glaucoma is the second-leading cause of blindness and leading cause of irreversible 
blindness worldwide, having an estimation of 79.6 million glaucoma patients by 
2020 (Quigley et al. 2006) and by 2040, it will be 111.82 million (Tham et al. 2014). 
Worldwide, 13.5% of blindness is due to glaucoma (Thylefors et al. 1995). More 
than 50% of glaucoma patients are unaware of their disease at presentation (Reidy 
et al. 1998; Wensor et al. 1998; Mitchell et al. 1996). The case definition and clinical 
classification used in different glaucoma prevalence studies varies widely (Foster et 
al. 2002).These differences make it difficult for direct comparison of prevalence 
findings across studies. The global prevalence of glaucoma for 40-80 years age 
group is 3.54%; prevalence of POAG is highest in Africa (4.20%) and that of PACG 
is highest in Asia (1.09%). Men have 36% more chances to develop POAG than 
women. People of urban areas have 58% more risk of developing POAG than their 
rural counterpart. Glaucoma occurs more in elderly (Tham et al. 2014).  
Prevalence of OAG among racial and ethnic groups varies greatly. The Baltimore 
Eye Survey revealed higher prevalence of POAG in blacks (4.3%) than white 
(1.3%) among age group 40 years and above (Sommer et al. 1991). For Hispanics 
in USA, it was 2% (Quigley et al.2001). Glaucoma rates in Asians ranges from 1 to 
4% (Rudnicka et al. 2006). In 2007, it was estimated that 24,937 Canadians had 
severe vision loss due to glaucoma, corresponding to 3.1% of all vision loss. (Access 
Economics Pty Limited, 2009). 
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2.1.7 Risk factors  
2.1.7.1 Increased IOP 
The single most important modifiable risk factor for glaucoma is elevated IOP, 
though not all patients with elevated IOP develop glaucoma (Schmidl et al. 2015; 
Bahrami, 2006). The role of IOP in pathogenesis of glaucoma is supported from 
both clinical trials (Vass et al. 2007) and also from basic science research 
(Stammer et al. 2012; Tamm, 2009).  
2.1.7.2 Age 
Advancing age is a recognized risk factor for OAG, having a 4 to 10 times higher 
prevalence in the age group older than 40 years (Hollows and Graham 1966; 
Leibowitz et al.1980; Tielsch et al. 1991). A meta-analysis of multiple population-
based studies of POAG or PACG concluded that, OR of prevalence of POAG was 
1.73 with each decade increase of age (Tham et al. 2014).  
2.1.7.3 Family history 
Positive family history of glaucoma may increase the risk of developing glaucoma 
for individuals (Burr et al. 2007; Wolfs et al. 1998; Netland et al.1993). It is an 
important predictor for first-degree relative with glaucoma (Allingham et al. 
2011). However, prospective studies that examined the progression of glaucoma 
and family history did not find any significant association between them (Leske et 
al. 2003; AGIS, 2002). 
2.1.7.4 Ethnicity 
Ethnicity can affect IOP and thus influences glaucoma prevalence and incidence. 
African descent has higher prevalence of OAG whereas prevalence of ACG is 
more in Asian and Inuit populations (Friedman and Vedula 2006; Hatt et al. 2006; 
Burr et al. 2007; Schmier et al. 2007). Black people have an estimated 2 to 5 times 
higher incidence of OAG than white people (Giangiacomo and Coleman, 2009). 
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2.1.7.5 Myopia 
Patients with myopia have greater chance of developing OAG (Burr et al. 2007). 
Large population-based surveys (Quigley et al. 1999; Michell et al. 1999) and 
longitudinal studies (Phelps, 1982; Chihara et al.1997) also supported this fact. 
2.1.7.6 Migraine and peripheral vasospasm 
They may act as a risk factors for progressive glaucomatous optic nerve damage 
(Budenz et al. 2006; Mitchell et al. 1996). This supports some role for a vascular 
role in the pathogenesis of glaucoma. 
2.1.7.7 Long-term use of corticosteroids 
They are the main cause of drug induced glaucoma and associated with increased 
IOP (Adis International 2004; Tripathi et al. 2003). 
2.1.7.8 Vascular aspects 
Ocular vascular disturbance which may or may not be due to increased IOP or 
reduced ocular perfusion pressure may cause or contribute to glaucomatous 
damage as well as retinal ganglionic cell death (Cherecheanu et al. 2013; Flammer 
et al. 2002). 
2.2 Management of Glaucoma 
Glaucoma is generally a chronic, progressive life-long disease. Once diagnosed, 
the aim of management is to delay or halt the progression of optic nerve damage 
and visual field defect. The treatment plan needs assessing all risk factors for 
disease progression, access to healthcare, and lifestyle and life expectancy of 
patients (Allingham et al. 2011). The control of IOP, the most important 
modifiable risk factor, is the mainstay of treatment. 
2.2.1 Diagnosis of Glaucoma 
The diagnosis of glaucoma is a clinical one based on the collective evidence from 
a careful patient history, the essential elements of a comprehensive eye evaluation 
that includes assessment of IOP, central corneal thickness measurement, 
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gonioscopy.  Optic nerve head and retinal nerve fiber layer examination, is 
important in clinical practice (Lester et al. 2013). In essence the diagnosis is made 
when there are characteristic anatomical (cupping, decreased NFLT) or 
physiologic (visual field defects) optic nerve changes. 
2.2.1.1 Patient’s History 
As applicable for all other clinical scenarios, history of a new patient of glaucoma 
suspect (or referral) should include demographic information of the patient, chief 
complaints, ocular and non-ocular medical and surgical history, current and 
previous ocular and systematic medications, allergy history, as well as family 
history of ocular and non-ocular diseases.   
2.2.1.2 Comprehensive eye examination 
It is very important to obtain and document accurate baseline information of the 
comprehensive eye examination for assessing future progression of disease and 
response of treatment(s) initiated and modifications, as needed. 
2.2.1.2(a) Intraocular Pressure (IOP) and Central Corneal Thickness (CCT) 
Increased IOP is the most important modifiable risk factor for glaucoma and the 
main focus for the treatment. Goldmann applation tonometry (GAT), a contact 
method that needs corneal anesthesia, is the standard method for measuring IOP 
(Tonometry) with proper and regular calibration of the tonometer. Several 
readings should be obtained from each eye to get an average value of IOP. Serial 
measurement of IOP is also required due to diurnal variation of IOP. A number of 
non-contact devices (e.g., ocular response analyzer, ORA) are also available. 
Corneal biomechanics, most importantly CCT, substantially influence the results 
of tonometry. So, CCT should also be measured with a pachymeter (normal CCT: 
530-545 nm). Increased or decreased CCT may lead to an overestimation or 
underestimation of IOP, respectively (Barton and Hitchings, 2013b).  
2.2.1.2(b) Slit-lamp examination and Gonioscopy  
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To exclude primary angle closure glaucoma and secondary causes (e.g., angle 
recession, pigment dispersion and inflammatory forms of glaucoma), examinations 
of the cornea and anterior chamber are done with the slit-lamp. Gonioscopy, the 
gold standard for angle assessment (the outflow channels), is performed on slit-
lamp examination. Grading of depth of angle is done during gonioscopy. A wide 
range of angle abnormalities may be found including peripheral anterior 
synechiae, pigmentation of the trabecular meshwork, signs of intermittent 
iridotrabecular contact, new vessels and traumatic damage to the drainage angle as 
well as congenital abnormalities like Axenfeld-Rieger syndrome (Barton and 
Hitchings, 2013b).  
2.2.1.2(c) Dilated Fundus and Optic Disc Examination  
These examinations are a must for exploring signs of glaucomatous changes in the 
optic disc (including cupping of optic disc, optic disc hemorrhage, and retinal 
nerve fiber layer defects) and to obtain a stereoscopic view of posterior segment to 
exclude any abnormalities causing secondary glaucoma (i.e., diabetic retinopathy, 
evidence of surgery for previous retinal detachment, lens abnormalities). The 
retinal nerve fiber layer, viewed with red-free illumination, should be studied 
carefully to detect any loss which strongly favors glaucomatous pathology. 
Meticulous examination for evidence of thinning of the neuroretinal rim should 
also be done (Barton and Hitchings, 2013b; Allingham et al. 2011). 
2.2.1.2(d) Vertical Cup:Disc Ratio (CDR)  
A large ratio suggests glaucoma or more rarely other pathology. Wide range of 
CDR values in normal population reduces its sensitivity for glaucoma diagnosis to 
less than perfect. (European Glaucoma Society, 2008). 
2.2.1.2(e) Visual Field assessment and Perimetry 
An integral part of a full ophthalmic examination, visual field assessment, 
performed with manual or automated perimetry, is essential for diagnosis of 
glaucoma and assessing baseline status and disease progression rate over time. 
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This test is subjective and needs patient cooperation and good response. Each eye 
should be tested separately and any refractive lens correction for the patient, if 
needed, should be in place. Abnormal visual field is a sign of a lesion anywhere in 
the visual system from the retina to the visual cortex of the brain. Therefore, visual 
field defect of glaucoma must be supported and co-related with other 
glaucomatous findings of retina and optic disc and tonometry. Kinetic (moving 
target) and Static (stationary target) perimetry are the two major types of 
perimetry. In static perimetry, a flashing dim light is used in one area of visual 
field with increasing intensity or size until the patient can recognize it. A complete 
visual profile is created by repeating the whole process. In kinetic perimetry, light 
intensity and size are fixed. The light is placed on the periphery of visual field and 
then gradually moves centrally until the patient visualizes it. A visual field 
boundary is then mapped by repeating the whole procedure (Cummings and 
Malouf, 2014). The present day accepted standard way of measuring the visual 
field is Automated Static Perimetry. Other automated perimetry include Short 
Wave Automated Perimetry, Frequency Double Technology (FDT) Perimetry, 
High-Pass Resolution Perimetry, Random Dot Motion Perimetry. Manual 
Perimetry includes Tangent Screens, Arc and Bowel Perimeters (Broadway, 2012; 
Barton and Hitchings, 2013b; Allingham et al. 2011). 
2.2.1.2(f) Optic Nerve and Retinal Nerve Fiber Layer (RNFL) Imaging for 
Structural Evaluation 
Numerous imaging methods to evaluate the structural changes of the optic disc 
and retina remain a mainstay for the diagnosis and management of glaucoma. 
Optical Coherence Tomography (OCT), developed in 1990 and available to 
ophthalmologists in 1996, provides quantitative and objective assessments of the 
optic disc, macula, RNFL in glaucoma by constructing cross sectional images and 
measuring the delay time of the echo of a backscattering low-coherence infrared 
(843-nm) diode light source. The light source is divided into reference and sample 
24 
 
path. Reflected sample light from patient’s eye provides an interference signal 
with the reference beam detected and recorded by a fiber-optic interferometer. 
OCT is a non-contact method performed with the patient seating upright at a slit-
lamp like headrest. Confocal Scanning Laser Polarimetry can be used to measure 
RNFL thickness as well. The retinal thickness can be measured by Retinal 
Thickness Analyzer. All these devices generate reproducible, quantitative 
measurements (Meira -Freitas et al. 2013; Barton and Hitchings, 2013b; 
Allingham et al. 2011) and have therefore become the gold standard for structural 
assessment of glaucoma nerve damage. 
2.2.1.2(g) Ocular Perfusion 
In patients with normal-tension glaucoma or Raynaud’s phenomenon, ocular 
perfusion may be reduced (Barton and Hitchings, 2013b). Progressive worsening 
of glaucoma despite well controlled IOP may be due to ocular hypo perfusion. In 
such circumstances, ocular blood flow measurement may be of value. Several 
methods for quantitative, comprehensive study of retinal, choroidal, and 
retrobulbar circulations include vessel caliber assessment, pulsatile ocular blood-
flow measurement, scanning laser fluorescein and indocyanine green (ICG) 
angiography of the peripapillary choroid and the retinal circulation. Laser Doppler 
flowmetry, confocal scanning laser Doppler flowmetry, and color Doppler 
imaging have been developed in the past two decades (Harris et al. 1999). 
2.2.2 Planning of Treatment 
As glaucoma is a chronic disease, long-term planning supplemented by a holistic 
approach to the individual patient, including education of the condition is needed. 
The aim of treatment for a glaucoma patient is to halt or delay the glaucomatous 
progression and damage to the visual function, mostly by lowering the IOP to a 
target pressure set for individual patients based on the status of the optic nerve 
head and other risk factors for progression like CCT, increased age, positive 
family history, African heritage and myopia for POAG; Asian heritage and 
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hyperopia are considered risk factors for ACG. In general, a target of 20% to 30% 
reduction from baseline IOP is recommended. Establishing the target IOP is one of 
the most important decisions to preserve the visual function and best possible 
quality of life for the patient. It needs careful assessment and modification of 
target IOP, if warranted, at each follow-up visit. Elevated IOP without 
glaucomatous damage (i.e., ocular hypertension) may need careful follow-up only 
without initiation of treatment (Allingham et al. 2011). Proper treatments delay the 
progression in early glaucoma patients (Leske et al. 2003; Leske et al. 1999). In 
advanced glaucoma, low IOP with minimal variation after treatment delays further 
progression of glaucomatous visual function defects (AGIS, 2000). 
2.2.3 Treatment Options for Glaucoma 
Currently available treatment option for glaucoma are: 
 Medication therapy, usually eye drops 
 Laser therapy 
 Surgery 
2.2.3.1 Medication therapy 
The field of glaucoma pharmacology was introduced by Sir Thomas Fraser when 
he mentioned the physiological action of the calabar bean (a source of 
physostigmine) in his publication (Realini, 2011; Fraser, 1867). The basic 
pharmacokinetics of topical glaucoma medications that include absorption, 
distribution, metabolism and elimination of an administered drug should be taken 
into consideration while prescribing (Mishima, 1981). Currently available major 
classes of topical medications for glaucoma treatment are as follows: 
 Prostaglandin analogues (PGAs)   
 Beta-adrenoceptor antagonists 
 Adrenoceptor agonists 
 Carbonic anhydrase inhibitors (CAIs) 
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 Cholinergics (acetylcholine receptor agonists) 
                                                 (Marquis and Whitson.2005; Allingham et al. 2011) 
2.2.3.1(a) Prostaglandin analogues (PGAs)  
Since their introduction in 1996, PGAs have changed the scenario of glaucoma 
therapeutics and become the choice of first-line pharmacotherapy for lowering 
increased IOP (Realini, 2011; Soltau and Zimmerman, 2002). In 1982, Hungarian 
physiologist Lazlo Bito developed the prototype molecule latanotoprost at 
Columbia University, after he and Carl Camras revealed that, in both healthy and 
glaucomatous monkeys, PGF2α (Prostaglandin F2α, a naturally-occurring  
prostaglandin) lowers the IOP (Camras and Bito, 1981). It took 14 years to 
develop an approvable formulation of latanotoprost (0.005%). In 2001, two other 
PGAs, travoprost (0.004%) and bimatoprost (0.03%) came into the market 
(Realini, 2011). They are administered once daily before bedtime and control 
diurnal fluctuation of IOP. (Asrani et al. 2000; Bergea et al; 1999).  
The PGAs are lipophilic, multi-carbon chain molecules derived from arachidonic 
acid. They lower IOP by increasing outflow of aqueous humor, primarily through 
the uveoscleral pathway (Mishima et al. 1997) and also through the TM pathway 
(Ziai et al. 1993). They also relax the ciliary muscle (Crawford and Kaufman).  
Patients tolerate PGAs well. Fewer topical applications with fewer severe side 
effects rank PGAs as most commonly prescribed glaucoma medication.      Ocular 
adverse effects include conjunctival hyperemia, eyelash growth, and increased iris 
pigmentation (due to increased melanin production within iris melanocytes after 
long-term use (Marquis and Whitson, 2005; Watson and Stjernschantz, 1996; 
Netland et al. 2001; Sherwood and Brandt, 2001). Systemic adverse effects 
include headache and upper respiratory tract symptoms. Exacerbation of anterior 
uveitis (Fechtner et al. 1998), cystoid macular oedema (CMO) after complicated 
cataract surgery (Ayyala et al. 1998; Callanan et al. 1998) have been reported with 
latanotoprost use. 
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2.2.3.1(b) Beta-adrenoceptor antagonists 
Tonic sympathetic stimulation mediates the formation of aqueous humor in the 
ciliary body (Wax and Molinoff, 1987).  Most of the β-adrenoceptor antagonists 
block both β1 and β2 receptors and decrease the production of aqueous humor 
(Alward, 1998). They are used as a component in many fixed-combination 
preparations as well as adjuncts and initial monotherapy (Barton and Hitchings, 
2013c). The topical use of propranolol, the first β-adrenoceptor antagonists found 
to decrease IOP, caused corneal anesthesia preventing its further use. Timolol 
(0.25% and 0.5%), the most popular topical non-selective β1 and β2 adrenergic 
antagonist, was introduced in 1978 in the USA. It is used twice a day. The US 
FDA considers timolol as ‘gold standard’ for glaucoma pharmacotherapy. All-new 
glaucoma medications are compared against timolol for FDA approval. 
Levobunolol (0.25% and 0.5%), carteolol (1.0%), metipranolol (0.3%) are also 
used twice daily (Marquis and Whitson, 2005). Reported ocular adverse effects 
include conjunctival hyperemia, stinging, superficial punctate keratitis and 
worsening dry eye symptoms (Coakes et al. 1981). Bradycardia, arrhythmia, 
cardiac block, congestive heart failure and bronchospasm are known systemic 
adverse effects. CNS adverse effects like depression, anxiety, fatigue, impotence 
and hallucinations have also been reported (McMahon et al. 1979; Van Buskirk, 
1980; Fraunfelder, 1980).  
Betaxolol (0.25% and 0.5%), applied twice daily, is a cardioselective B1-
adrenoceptor antagonist. It is a less effective IOP lowering agent than timolol and 
other non-selective agents, but has shown to be more effective in preserving visual 
field than timolol (Collignon-Brach, 1992; Messmaer et al. 1991). Other than 
occasional stinging after instillation, there are almost no ocular adverse effects. 
Systemic adverse effects, if any, are also less pronounced than the non- selective 
agents (Schoene et al. 1984).  
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2.2.3.1(c) Adrenoceptor agonists 
As part of the sympathetic nervous system, α-adrenergic receptors have an 
important role to regulate aqueous humor dynamics. Drugs in this class lower IOP 
by increasing aqueous outflow through trabecular meshwork and uveoscleral 
pathway or decreasing production, or both. Epinephrine is a non-selective 
adrenergic agent that stimulates both α- and β- adrenoceptors within the eye. It 
was commercially available in 1950s as topical glaucoma medication and is rarely 
used now (Realini, 2011; Marquis and Whitson, 2005; Townsend and Brubaker, 
1980). Ocular adverse events of epinephrine include pupillary dilatation, 
conjunctival hyperemia and ocular irritation (van Alphen, 1976). Systemic adverse 
events include headache, palpitation, high blood pressure and anxiety.  
Clonidine, a highly lipophilic molecule with α2- and some α1- adrenoceptor 
agonistic activity, readily crosses the blood-brain barrier having systemic 
hypotension as an adverse effect when instilled topically into eyes. It is still in use 
in part of Europe (Marquis and Whitson, 2005). Apraclonidine or para-
aminoclonidine (available in 0.5% and 1.0% concentration), a serendipity 
derivative of clonidine, is a highly hydrophobic molecule (less likely crosses the 
blood-brain barrier with relatively selective α2-adrenoceptor agonistic activity. It is 
not used for a prolonged period due to high rate of blepharoconjunctivitis (Butler 
et al. 1995). Tearing and foreign body sensation may occur with ocular instillation 
(Wilkerson et al. 1991).  
Brimonidine, a highly selective α2-adrenoceptor agonist, is used more commonly 
as adjunctive therapy for long-term use, though monotherapy is not unusual. It is 
also used to prevent post-operative IOP spike following anterior segment laser 
therapy. Brimonidine 0.2% (with benzalkonium chloride as a preservative) is used 
for two or three times a day (Marquis and Whitson, 2005). Allergic 
blepharoconjunctivitis is seen in 12%-15% of patients after several months use 
(Schuman, 1996; Schuman et al.1997). Dry mouth, fatigue and headache may 
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occur with use of brimonidine. A new formulation of 0.15% brimonidine with 
stabilized oxychlorocomplex as a preservative shows lower rate of fatigue, dry 
mouth, and conjunctival hyperemia (Katz, 2002). Brominidine should not be used 
in children due to chance of CNS and respiratory depression (Marquis and 
Whitson, 2005). Concomitant use of brimonidine and/or apraclonidine with mono-
amino oxidase inhibitors (MAOIs) is contra-indicated (Barton and Hitchings, 
2013c).  
2.2.3.1(d) Carbonic anhydrase inhibitors (CAIs) 
Belonging to the sulphonamide group of drugs, CAIs are available in both oral and 
topical form. They inhibit the catalyst carbonic anhydrase isoenzyme II in the 
ciliary epithelium to suppress the conversion of CO2 and H2O to HCO3- and H+, 
thus decrease aqueous humor formation (Marquis and Whitson, 2005). 
Acetazolamide, the first systemic CAI introduced in 1954, is available in 125 mg 
and 250 mg and a sustained-release capsule form of 500 mg with twice daily 
dosing. Methazolamide (25 mg and 50 mg), weaker and slightly less effective than 
acetazolamide, is often better tolerated by patients with twice or thrice daily 
dosing. Despite effectiveness in lowering IOP, their clinical use is limited due to 
several and often very bothersome  adverse effects, including hands and feet 
paresthesia, nausea, vomiting, fatigue, weight loss, metabolic acidosis, low serum 
potassium (hypokalemia), low serum sodium (hyponatremia). They are reserved 
for short term use in a patient with maximally tolerated medical therapy and often 
before ocular surgery to control raised IOP (Realini, 2011; Marquis and Whitson, 
2005).  
Dorzolamide (2.0%) was the first topical CAI introduced in 1994. In 1998, another 
topical CAI, brinzolamide (1.0%) became available. Both are used three times a 
day. Topical CAIs have much fewer adverse events than systemic CAIs. Ocular 
adverse effects include stinging, burning and itching (Realini, 2011; Marquis and 
Whitson, 2005). In patients with marked endothelial compromise, irreversible 
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corneal decompensation may occur (Konowal et al. 1999). Brinzolamide has better 
patient tolerability than dorzolamide (Silver, 1998). All forms of CAIs should be 
avoided in patients with sulfonamide hypersensitivity (Marquis and Whitson, 
2005). Unfortunately topical CAIs are much less effective than oral CAIs thus 
relegating them to third or fourth line agents. 
2.2.3.1(e) Cholinergics (acetylcholine receptor agonists, parasympathomimetic) 
Also known as miotics, they are the oldest glaucoma drugs introduced in the 1870s 
(Alward, 1998). At neuromuscular junction, they stimulate parasympathetic 
receptors. As a result, there is contraction of the longitudinal muscle of the ciliary 
body that pulls on the scleral spur and opens the trabecular meshwork and 
schlemm canal causing increased aqueous outflow (Kaufman et al. 1976) and 
subsequent reduction in IOP. They are of two types: direct-acting cholinergics, 
work on the parasympathetic receptors in the eye and indirect-acting cholinergics, 
work by inhibiting acetylcholinesterase enzyme and results in decrease 
degradation of acetylcholine (Marquis and Whitson.2005).  
Pilocarpine, the most commonly prescribed topical short direct-acting cholinergic 
compound, is available in a range of 0.5% to 4.0 % concentration with four times a 
day dosing. A topical gel form to be applied at bedtime is also available. 
Diminished visual acuity, fixed small pupil and induced myopia are often and 
retinal detachment is rarely reported ocular adverse effects. Frontal headaches 
above the eye can be very bothersome. Systemic adverse effects are uncommon 
and include increased salivation and sweating, diarrhea, vomiting and tachycardia. 
Although effective and inexpensive, it is not used that much today because of its 
ocular adverse effects and multiple dosing requirements and availability of 
alternatives. Ecothiophate iodide and demecarium bromide are indirect-acting 
cholinergics. As like pilocarpine, they are available in multiple concentrations and 
are used twice a day. They deplete systemic cholinesterase and 
pseudocholinesterase. They are used for treatment of glaucomas in aphakia and 
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pseudoaphakia in many parts of Europe and Latin America (Marquis and 
Whitson.2005). Chronic use of ecothiophate iodide may predispose tocataract 
formation (Thoft, 1968).   
2.2.3.2 Laser Therapy  
A significant advancement in the treatment of glaucoma was the introduction of 
light amplification by stimulated emission of radiation or laser during the second 
half of the 20th century.  Lasers are now commonly used to treat various forms of 
glaucoma including open angle glaucoma, pseudoexfoliative syndrome and 
pigmentary glaucoma (Mainster et al. 1983; Peyman et al. 1984, Allingham et al. 
2011). 
2.2.3.2(a) Basics and Properties of Laser Energy 
The basis of laser technology is based on the Quantum Theory of Radiation by 
Albert Einstein, where he hypothesized that   the photon, the tiny packets or 
particles of light, has discrete quantum of energy proportional to its wavelength 
(Einstein, 1917). Laser energy has distinct properties. Light emitted by lasers 
causes the photons to be synchronized (coherence). A small focal spot can be 
created when the laser is delivered through an optical system (commonly a slit-
lamp biomicroscope) resulting in a nearly parallel beam with limited divergence 
(collimation), with only one discrete wavelength (monochromacy) and high 
intensity (Allingham et al. 2011).  
2.2.3.2(b) Laser effects on target tissue.  
Laser therapy for glaucoma causes photocoagulation (local inflammation and 
scarring) of target tissue or photovaporization (vaporization of intracellular and 
extracellular fluids), facilitated by short exposure time and high-energy level and 
an area of exposure that reduce heat conduction and creates a noninvasive incision 
in the tissue. Thermal effect depends on wavelength of the light, duration of 
exposure and amount of light energy per area of exposure. Lasers with 
wavelengths between 400 to 600 nm are most useful for these procedures as 
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Melanin, the pigment of most target tissues, has a peak absorption in the blue-
green portion of the visible spectrum. High intense energy of laser in a very small 
area of target tissue for an ultra-short period of time causes ionizing reaction 
resulting in photodisruption, a technique in ophthalmology utilizing lasers to form 
a gaseous state called plasma, which then causes acoustic shock waves that can 
disrupt both pigmented and non-pigmented structures. The most common 
application of this technology being excimer laser technology to treat refractive 
errors. Thermal effects also play a role in photodisruption mechanism (Mainster et 
al. 1983; Allingham et al. 2011).  
2.2.3.2(c) Laser Delivery Units and Laser Types for Glaucoma Treatment 
A slit-lamp biomicroscope is used by most laser units. In an articulated arm, a 
system of fiber optics or mirrors guide the laser beam from the laser tube, through 
the slit-lamp, into the patient’s eye. Other laser delivery systems use contact 
probes attached to the fiber optics. For positioning and focusing of the laser beam 
in the visual spectrum, an aiming laser beam of attenuated energy can be used. For 
laser beams with wavelengths outside the visual spectrum, an additional laser 
(e.g., helium-neon), or semiconductor diode, with wavelength of 633 and 640 nm, 
respectively, is used. The control unit of most laser systems include spot size (in 
microns), exposure duration (milliseconds, microseconds or nanoseconds), and 
energy (joules or millijoules) or power (watts or milliwatts). Most commonly used 
lasers for glaucoma are argon, Nd: YAG, and semiconductor diode. They 
primarily differ by the medium in which the atom exists that causes the stimulated 
emission of photons (Allingham et al. 2011).      
2.2.3.2(d) Argon Laser Trabeculoplasty (ALT) 
Since Krasnov reported a temporary control of IOP in open -angle glaucoma in 
1973 by using ultra-short ruby laser pulses (Krasnov, 1973), control of open angle 
glaucoma by treating trabecular meshwork with laser has been a common 
treatment in the field of ophthalmology. Wise and Witter first reported a series of 
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56 eyes of diagnosed open angle glaucoma patients treated with argon lasers 
applied 360 degree to the trabecular meshwork and concluded that, treatment of 
open angle glaucoma with argon laser (laser trabeculoplasty) was an effective 
alternative to filtration surgery in phakic eyes (Wise and Witter, 1979). Argon gas 
is the medium in the argon laser delivery system. The wavelength is in the blue 
(488nm) and green (514 nm) portions of visible spectrum and is optimum for 
absorption by melanin. Green only argon light may be safer for the 
ophthalmologist with equivalent efficacy of lowering IOP. The procedure is 
performed at the slit lamp with gonioprism placing evenly spaced 50-100 
nonpenetrating argon laser spots to the TM over 180° - 360° of the angle to 
produce thermal burns around the circumference of the  TM. Commonly used 
parameters are spot size (50µ), pulse duration (0.1 sec) and power (400-800 mW) 
(Marqquis and Whitson, 2005). The precise mechanism of improved aqueous 
outflow and IOP reduction by ALT is still unclear. Heat-induced shrinkage and 
tightening of treated trabecular meshwork cells may contribute to the mechanism 
(Babizhayev et al. 1990). It has also been postulated that ALT reduces the 
trabecular cell density by eliminating them partially, and the remaining cells 
produce a different composition of the extracellular matrix with improved outflow 
properties (Van Buskirk et al.1984; Kimpel and Johnson, 1992). The cellular 
response and the tissue remodeling after initial mechanical injury by ALT 
probably result in an improved aqueous outflow and IOP reduction (Van Buskirk, 
1989). In the histopathological study of autopsy eye, Kramer and Noecker (2001) 
found coagulative damage with ablation craters at the base and edge within the 
uveal meshwork following ALT. Due to the initial damage to the targeted tissues, 
repeat ALT is not effective in lowering IOP. (Feldman et al. 1991; Weber et al. 
1989). However, efficacy of ALT in lowering IOP is equivalent compared to 
medications (The Glaucoma Laser Trial Research Group, 1990). Complications of 
ALT include transient IOP elevation (Frucht et al. 1985), iritis (Thomas et al. 
1982) and PAS (scar) formation (Hoskins et al. 1983). 
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2.2.3.2(e) Selective Laser Trabeculoplasty (SLT) 
Latina and Park reported that, when the energy of a Q-switched (to allow 
photodisruption), frequency doubled, 532 nm Nd: YAG lasers (neodymium atoms 
are embedded in a crystal of yttrium-aluminium-garner) with pulse durations 
ranged from 10 nsec to 0.1 sec was used in a mixed cell culture of pigmented and 
nonpigmented TM cells, it selectively targeted pigmented trabecular meshwork 
cells without causing structural damage to non-pigmented cells (Latina and Park, 
1995). The mechanism is based on the principle of selective photothermolysis, 
whereby absorption of a suitable brief optical radiation with inherent optical and 
thermal properties causes selective damage to target cells and destroys 
melanosomes within melanocytes that minimize thermal injury to surrounding 
structures (Anderson and Parrish, 1983). The desired target cell must have an 
intracellular chromophore with greater optical absorption at the laser wavelength 
than its surrounding tissues and the duration of laser must not exceed the time 
required for thermal diffusion into the tissue (thermal relaxation time) (Kagan, et 
al. 2014). The precise mechanism of action of IOP lowering effect of SLT is not 
fully understood, but several potential biological and mechanical mechanisms, 
particularly cytokine secretion, matrix metalloproteinase induction, increased cell 
division, repopulation of burn sites and macrophage recruitment may be vital. 
Clinically, the energy level of SLT is titrated until the appearance of microbubbles 
(Latina and de Deon, 2005). 
 In the same histopathological study by Kramer and Noecker (2001), those human 
autopsy eyes having SLT showed only disruption of trabecular endothelial cells, 
possibly resulted from the cracking of intracytoplasmic pigment granules. 
Coagulative damage or disruptions of the corneoscleral or uveal trabecular 
endothelial beams were not observed. This finding suggests, at least theoretically, 
SLT may be a potential repeatable procedure.  
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SLT is now a widely used and acceptable procedure for treatment of glaucoma at 
both patient and ophthalmologist level. Many ophthalmologists suggest SLT even 
as first line of treatment for OAG (Melamed et al. 2003; Nagar et al. 2005; 
McIlraith et al. 2006). SLT as initial treatment of glaucoma results in fewer 
treatment steps to maintain the target IOP and slower progression to blindness or 
invasive surgery when compared to medications as initial treatment (Katz et al. 
2012). SLT is also effective in lowering IOP when previous ALT failed (Latina et 
al. 1998; Birt, 2007). As like ALT, SLT produces equivalent IOP reduction to 
medications (Melamed et al. 2003; McIlraith et al. 2006). SLT success is 
significantly predicted by baseline IOP. (Hodge et al. 2005). 
There is a paucity of well designed, especially prospective studies for assessing 
the safety and efficacy of SLT (Ayala and Chen, 2011). Study of safety and 
efficacy of repeatability of SLT is even less studied. A few retrospective studies 
have demonstrated that, repeat SLT in POAG patients had similar efficacy to 
initial SLT (Avery et al. 2013; Hong et al. 2009). Another retrospective study 
revealed successful IOP lowering effect of repeat SLT in eyes that did not achieve 
desired IOP reduction after initial SLT (Khuri et al. 2014). A prospective study 
demonstrated an 86% (26 out of 30 eyes) success rate of repeat SLT (Lai and 
Bournias, 2005). The fact that this repeatability issue has not been well studied 
prospectively is the cornerstone issue for this clinical trial. 
IOP spike immediately after SLT may be a potential complication that can be 
prevented by using topical α-agonist in the perilaser period and ensuring titration 
of energy to just produce microbubbles in the target tissue. (Waisbourd and Katz, 
2014). Other complications include uveitis (Kim and Singh, 2008), corneal edema 
(White et al. 2013), hyphema (Shihadeh et al. 2006), macular burn (Liyanage et al. 
2014), and irreversible IOP spike, especially with heavily pigmented TM 
(Harasymowycz et al. 2005). 
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Comparison of ALT and SLT 
The first clinical trial comparing IOP lowering effect of ALT and SLT was 
conducted by Damji et al. (1999) that revealed equivalent reduction in IOP at 1-
year follow up. In their review of 145 articles, Sample et al. (2011) concluded that, 
Laser trabeculoplasty is successful in lowering intraocular pressure for patients 
with open-angle glaucoma, but they did not find any literature establishing the 
superiority of any particular form of laser trabeculoplasty. The efficacy of both 
lasers compared to each other and also to different pharmacotherapies are 
equivalent. Their complications are also similar (Marquis and Whitson). SLT has 
the theoretical advantage of repeatability that has yet to be established with a 
sufficiently powered randomized prospective clinical trial-which is what we are 
doing in this clinical trial.  
2.2.3.2(f) Surgical Options 
When medical or laser therapy fails to control glaucoma, surgical options have to 
be considered. The glaucoma surgery aims to either increases the outflow or 
decreases the production of aqueous humor (Razeghinejad and Spaeth, 2011). As 
such, glaucoma surgery has two basic approaches- 
(a) Aqueous humor outflow increasing surgery:   
In 1856, Graefe observed that glaucoma, particularly acute attack, could be 
controlled with iridectomy. In 1867, De Wecker did anterior sclerotomy, the first 
filtration surgery to make a ‘filtration cicatrix’ with a full-thickness scleral 
incision 1 mm posterior to the limbus, through which intraocular fluid might 
escape the anterior chamber. This formed the basis of ocular filtration surgery 
(Hirschberg, 1994). Modern trabeculectomy techniques started over 30 years ago 
(Cairns, 1968). It involves making a fistula underneath the scleral flap into the 
anterior chamber to allow the aqueous humor to pass through it into the bleb in the 
subconjunctival space, thus reducing the IOP. Surgical scar formation is a 
potential limiting factor for long-term success (Marquis and Whitson, 2005), that 
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can be delayed or halted to some extent by post-operative use of anti-fibrotic 
agents (fluorouracil, mitomycin), thus extending the duration of trabeculectomy 
success (Ruderman et al. 1987; Palmer, 1991). Complications of trabeculectomy 
include hypotony, cataract formation, choroidal effusion or hemorrhage, and 
endophthalmitis (Marquis and Whitson, 2005). In non-penetrating trabeculectomy 
(NPT), the innermost layer of trabecular meshwork is kept intact, so the aqueous 
humor can gradually pass through under the scleral flap (Zimmerman et al. 1984). 
Although NPT has fewer early post-operative complications, its effectiveness, 
when compared to standard trabeculectomy, is also less. (Chiselita, 2001). 
When trabeculectomy fails, drainage device implant surgery can be performed. 
Usually, a silicone drainage tube is implanted from the anterior chamber to a plate 
or disc below the subconjunctival space (Marquis and Whitson, 2005). A number 
of valved (Krupin and Ahmed) and non-valved (Baerveldt, Molteno, Schocker, 
Ex-PRESS) devices are available (Razeghinejad and Spaeth, 2011). 
The Ex-PRESS shunt, introduced in 1998, is a biocompatible, stainless steel 
device, placed under a partial thickness scleral flap. It is often used in conditions 
such as  aphakia, uveitic glaucoma, and pseudoaphakia (Nyska et.al. 2003). 
The iStent, is a heparin coated, non-ferromagnetic, 1 mm long L-shaped stent, 
introduced in 2001 for trabecular meshwork micro-bypass procedures, that 
reroutes the aqueous from the anterior chamber directly into the Schlemn’s canal 
(Razeghinejad and Spaeth, 2011). Preliminary result of this procedure is 
encouraging, but studies with long term follow-ups are warranted for further 
evaluation (Nichamin, 2009; Fea, 2010). 
(b) Surgery for decreasing aqueous humor inflow: 
These are cyclodestructive procedures, the last resort to control glaucoma 
refractory to medical and other surgical therapies, involving destruction of part of 
the ciliary body, thus decreases the production of aqueous humor and reduces IOP 
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(Marquis and Whitson, 2005).  These procedures include cyclocryotherapy 
(deRoetth, 1966), cyclodiathermy (Dunphy and Albaugh, 1941), and laser 
cyclophotocoagulation (Peyman et al. 1990). 
2.3 Economic Evaluation of Healthcare: An Overview  
In every corner of life, scarcity of resources prevails. There are no exceptions.   
Hence a series of pragmatic decisions in a systematic manner for optimum use of 
limited resources for the maximum benefit of stakeholders is needed (Hurley, 
2000). The decision of resource allocation for healthcare is even more difficult. 
Rapid accumulation of medical information and availability of different 
technologies for the same  medical condition often offers complicated situations to 
decide which treatment option for the given condition would carry the best results 
at both individual and policy level (Petitti, 2000). Mounting pressure on healthcare 
budgets in every country force policy makers to consider the costing aspect of a 
given treatment modality along with its clinical effectiveness to maximize 
outcome and minimize costs. Economic evaluation is the comparative analysis of 
alternative course of action in terms of both their costs (input) and consequences 
(outcomes, effects). It provides a framework to make the best use of clinical 
evidence through organized analysis of effects of all available alternatives on 
health, healthcare cost and other issues deemed valuable. Economic and clinical 
evaluations for a given medical condition are complementary to each other. 
(Drummond et al. 2015).  
Some key aspects of a good economic evaluation are as follows: 
Formation of a Clear Evaluation Question: 
As with any good research analysis, the carefully articulated question of an 
economic analysis should clearly reflect the goals and objectives of the 
interventions under consideration with outcome measures to judge the 
interventions (Seflon, 2000).  
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Defining Effectiveness of Intervention and Measuring and Valuing Outcome: 
For linkage of cost to effect in an economic evaluation, assessment of 
effectiveness of the interventions along with value of outcomes or benefits 
are vital. Conclusion about the effectiveness is often more criticized than 
costing of interventions (Clyne and Edwards, 2002).  
Comparison of Competing Alternatives: 
This is, perhaps, the most central feature of an economic evaluation. Within 
a specific context, costs and effectiveness of specific interventions or 
programs in comparison should be made (Clyne and Edwards, 2002). 
 Defining the Perspective: 
The costs and consequences of an economic evaluation are determined 
critically by its perspective. The cost can be estimated from the perspective 
of society. This societal perspective includes all the accrued costs and 
consequences for a given situation. In perspective from government, a 
sector, or even individuals, cost will be calculated according to the interest 
of the party involved (Drummond et al. 2015; Clyne and Edwards, 2002). 
 Assessing Costs: 
Careful cost assessment is a pivotal component of economic evaluation. 
Conducting a cost assessment not only includes the identification of 
alternatives and measurements of relevant cost items after establishing the 
perspective, discounting and monetary evaluation of benefits, but also the 
opportunity cost (relative to benefit) of the alternative uses (Shiell et al. 
2002). Often, “Do Nothing” alternative is used to establish a baseline 
comparator for resource use (Palmer and Reftery, 1999). The former may 
be more costly than the latter option, as individuals may inefficiently utilize 
a wide range of publicly provided alternatives (Browne, 1998).  Costs may 
be calculated item by item (microcosting) or based on an average or 
modeled estimate (macrocosting) 
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 Valuing Cost Items in Monetary Terms: 
Albeit cost estimates in economic evaluation should reflect the opportunity 
cost. In practice, direct costs are usually valued at the price paid for each 
item, termed as the market value (Clyne and Edwards, 2002). 
 Time Preferences and Discounting: 
Most interventions and programs, particularly in medical fields, continues 
over a long period of time. In such scenario, it is necessary to consider the 
time preference for money that measures the extent to which individuals 
prefer to have dollar or resources today rather in future (Hurley, 2000). 
Discounting reflects the loss in economic value due to delay in incurring 
cost or realizing benefit. So in health economic evaluation, a discount rate  
(usually 3% to 8%) is applied over all the number of years to be considered 
over all the accumulated expenditure and anticipated benefits to discount 
the future costs and benefits to the present (Petitti, 2000; Hurley, 2000).  
 
Although costs estimation across most   economic evaluations, in monetary units, 
has a common format, the approach of consequences or benefits estimation varies 
substantially (Hurley, 2000; Drummond et al. 2015). Four types of economic 
evaluations are most commonly used: 
 In Cost Effectiveness Analysis (CEA), consequences or benefits of 
different interventions are measured in natural units (e.g., life years gained, 
cases prevented, deaths avoided). Alternative interventions are then 
compared in terms of costs per unit effect achieved (Hurley, 2000) in the 
same outcome units. For evaluating the relative efficiency of two (or more) 
programs, the incremental cost-effectiveness ratio (ICER) that expresses the 
additional cost needed per additional unit of effect, is determined. For a 
comparison of competing programs P1 and P2,  the ICER is calculated as 
follows: 
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              Difference in costs between programs P1 and P2 
ICER =  
              Difference in health effects between programs P1 and P2 
 
CEA may identify the intervention with dominant position that achieves the 
desired outcome with lower costs over the other options considered 
(Drummond et al. 2015; Clyne and Edwards, 2002; Hurley 2000). 
 
 In Cost-Utility Analysis (CUA), the outcomes of the interventions are 
measured in terms of Quality-Adjusted Life Year (QALY) keeping all other 
structures the same as CEA.  QALY is a measure that assesses the effect of 
a health intervention on both the quantity (length) and quality (as indicated 
by people’s subjective rating of the health state between 0 or immediate 
death and 1 or full health) of life. CUA is often addressed as an adaptation 
of CEA (Hurley 2000; Palmer et al. 1999). Its main use is to compare costs 
on outcomes that may be similar enough to compare but do not have the 
same exact outcomes (e.g. death from breast cancer with morbidity from 
severe eczema). 
 
 In Cost-Benefit Analysis (CBA), outcomes of interventions are valued in 
monetary terms by either human capital approach or willingness to pay. In 
human capital approach, health gain is valued against accompanying 
increase of a person’s wage rate (market productivity). In willingness to 
pay, health gain is valued against the amount the person is willing to pay to 
achieve the health gain.  For programs P1 and P2, net benefit can be 
calculated from CBA as follows: 
 
Net Benefit = (Benefit P1- Benefit P2) - (Cost P1-Cost P2). 
If the net benefit is positive, implementation of the program P1 would 
increase welfare of society and vice versa (Hurley, 2000). CBA is not used 
nearly as much as CEA or CUA. 
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 In Cost-Minimization Analysis (CMA), the interventions are compared 
only on their costs to determine the least-expensive option, as the 
effectiveness (or outcome) of the interventions is the same qualitatively and 
quantitatively. This condition is not often met in real situations (Clyne and 
Edwards, 2002; Petitti, 2000). 
Several types of uncertainty are associated with method of analysis of economic 
models. Sensitivity analysis can help the reviewer to determine which parameters 
are the key drivers s of a model’s output. One-way sensitivity analysis assesses the 
impact of changes of certain parameters, one at a time, on the model’s conclusion. 
Probabilistic sensitivity analysis quantifies the level of confidence to the 
conclusions of an economic evaluation (Taylor, 2009; Petitti, 2000). 
2.4 Trial Based Economic Evaluation 
When economic data are collected in a randomized control trial (RCT), it can 
serve as the basis for an economic evaluation study and can be termed as ‘Trial 
Based Economic Evaluation’ (Ramsey et al. 2015). When randomization is proper 
in different study arms, RCT provides high internal validity with good 
effectiveness data of interventions among different arms. Patient-specific data on 
both costs and consequences (outcomes) are used to estimate mean cost and mean 
health outcomes for an incremental analysis.  However, there are some issues and 
problems needed to be addressed by the researchers in such a setting of economic 
evaluation. Some RCTs may lack generalizability to the target population of 
interest. Effectiveness or outcome measurement in an explanatory RCT may not 
mimic the real practicing intervention scenario and thus may over-estimate or 
under-estimate the cost-effectiveness analysis. Inadequate patient follow-up may 
adversely affect the economic evaluation (Drummond et al. 2015). Schwartzand 
and Lellouch (1967), introduced ‘pragmatic approach’ along with ‘explanatory 
approach’ of RCT. A compromise between the goals of internal validity and 
generalizability with the aim to evaluate the effectiveness or cost-effectiveness of 
43 
 
the intervention to reflect the ‘real world’ condition when the intervention will be 
in routine use, may support an economic evaluation (Drummond et al. 2015). 
Thorpe et al. (2009) developed  the Pragmatic-Explanatory Continuum indicator 
Summary (PRECIS) to assess and display the position of any given trial within 
this continuum to help trialists to assess the degree to which design decisions align 
with the trial’s stated purpose of either supporting pragmatic approach (decision 
making) or explanatory approach.  
2.5 Markov Modelling 
Markov modeling allows presentation and analysis of random and repetitive 
process over time in a decision tree. It is particularly suitable for chronic disease 
with recursive nature. The disease in question is divided into distinct states, known 
as Markov states over a series of discrete time period with the transition 
probabilities of occupying a given state known as Markov cycle. During each 
cycle, the patient may move from one state to another. The length of the cycle 
should represent a clinically meaningful time-interval. During the modelling 
process, a patient may stay to the same state or may transit to another state at the 
end of the cycle. A Markov process ultimately needs the ‘absorbing state’ when it 
is impossible for patient to move from the state or the patient dies. Two other less 
applied but useful Markov states are temporary state and tunnel state. Temporary 
state is used for a short event when a patient can stay at that state for a maximum 
of one cycle. When a temporary state lasts for more than one cycle and can transit 
in a fixed sequence, it is known as tunnel state. The Markov state should also 
represent a clinically and economically important event over a period of time. The 
transition probabilities of a Markov chain model are assumed constant over time. 
However, transition probabilities in health care are time dependent and may 
change with age, sex and other relevant characteristics of patients. Costs are 
typically assigned to each Markov cycle in line with the state of the patient. Health 
utility or effect and cost are calculated independently from each cycle. Costs and 
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health outcomes from all cycles are then added up. The expected costs and values 
of health outcomes of each Markov state are weighted by the time a patient spends 
in that state. The final expected values of cost and health outcome are derived 
from summing up weighted values of each cycle. Discounting for cost and health 
outcome (when appropriate) should be done using the defined formula of 
discounting. For survival duration, proportion of all alive patient in each state per 
cycle should be weighted by 1 and those who died should be weighted by 0. 
Adding the result would give the expected number of life -year of the cohort of the 
Markov model. To examine the robustness of the results of a Markov model, 
sensitivity analysis under variability of parameter uncertainty, analytical 
uncertainty, generalizability of results and structure uncertainty are performed. 
(Drummond et al.2015; Xin, 2007; Briggs and Sculpher, 1998; Sonnenberg and 
Beck, 1993). 
2.6 Economic Evaluation of Glaucoma  
Studies on the economic evaluation of glaucoma are limited with the majority 
addressing costs only (Rouland et al. 2005; Kobelt, 2002; Coyle and Drummond, 
1995). Several studies on the cost-effectiveness of glaucoma screening have been 
conducted. Gottlieb et al. (1983) introduced a measure of Quality Adjusted Year 
of Vision (QAYV) and performed a cost-effectiveness analysis of various 
screening methods of glaucoma in 40-79 years age group. They concluded that 
screening of age group 55-70 years were most cost-effective, tonometry was more 
cost-effective in younger groups and screening of the high-risk group for 
glaucoma was more cost-effective compared to general population. Boivin et al. 
(1996) did a cost-effectiveness analysis of glaucoma screening using opinion 
based estimates of the effectiveness of glaucoma for a three yearly screening of 
subjects 40-79 years, where perimetry was done if any abnormality was detected 
on fundoscopy and tonometry. Scenarios with different screening frequency, age, 
participation in screening, compliances with treatment, treatment efficacy, and 
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diagnostic tests were also examined. They did not find any proof that treatment of 
glaucoma or of high intraocular pressure from a screening standpoint would arrest 
the progression of glaucoma to blindness, even when treatment efficacy was 
assumed to be as high as 50%. They also concluded that, the cost-effectiveness of 
most glaucoma screening programs considered would not be competitive. Tuck 
and Crick (1997), in their cost-effectiveness study of different modes of 
screening/case-finding for glaucoma, concluded that glaucoma screening for 
people aged 40 years or more could be justifiable and likely to be economically 
beneficial when conducted with overall eye examinations.  
In their review of the economic burden of glaucoma, Rouland et al. (2005) found 
that, most costs were associated with direct medical costs, although non-medical 
costs were also substantial. Treatment costs were directly proportional to severity 
of disease and number of medications used and negatively correlated with 
treatment efficacy in reducing IOP. With introduction of costly but more potent 
and better tolerated medications, treatment costs also increased greatly.  
Using a Markov model with a 25-year time horizon, Stein et al (2012) compared 
the incremental cost-effectiveness of treating newly diagnosed mild OAG with 
PGAs, LTP, or observation only. They concluded, both PGAs and LTP were cost-
efficient options and if the assumption of optimal medical adherence was made, 
PGAs were more cost-efficient. However, they commented that, more realistic 
assumption of medical adherence (considering 25% less effective than the 
documented effectiveness reported in the clinical trial) might prove the other way 
round. 
Lee and Hutnik (2006) projected cost comparison of SLT (repeat treatment every 
2 or 3 years) versus glaucoma medication (mono-, di-, and tri-drug therapy 
groups) over the period of 6 years for OAG patients of Ontario aged 65 years or 
more. They found, at per-patient level, SLT offered a modest potential cost saving 
over primary medication regimens. However, the cost of surgery for failed SLT or 
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medical therapy and the cost for medical therapy in conjunction with SLT were 
not considered in this study.  
Seider et al. (2012) compared cost analysis of topical medications versus SLT 
assuming a societal perspective. SLT was less costly than most brand-name 
medications within 1 year and less costly than generic latanoprost and generic 
timolol after 13 and 40 months, respectively. However, they did not include 
complications after SLT, need for subsequent surgery, or transportation costs for 
patients in their analysis. 
Cantor et al. (2008) developed a Markov model to stimulate the transition of 
treatment progression and to compute and compare costs of glaucoma treatment 
for LTP, surgery and medication over a period of five years. They concluded that, 
laser trabeculoplasty was associated with the lowest total costs compared to 
treatment by medication alone or by filtering surgery for patients who were not 
adequately controlled by two medications. However, they mentioned that, due to 
limited availability of the transition probabilities in published literature, the model 
results needed to be validated by prospective or retrospective observational 
studies. 
At the time of writing this thesis, we did not find any study that computed and 
compared cost-effectiveness of ALT and SLT for treatment of OAG. This study 
aims to compute and compare the cost-effectiveness analysis of ALT versus SLT 
among uncontrolled open angle glaucoma patients (including ocular hypertension, 
pigmentary dispersion syndrome and pseudoexfoliation syndrome) who have had 
at least one previous full SLT, and are recruited in an ongoing clinical trial entitled 
‘A randomized clinical trial of laser trabeculoplasty (SLT) in open angle glaucoma 
who had been previously treated with complete SLT’. 
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Chapter 3 – Methods  
The objective of this study is to compute and compare the cost-effectiveness of 
repeat laser treatments (ALT versus SLT) among uncontrolled open angle 
glaucoma patients (including ocular hypertension, pigmentary dispersion 
syndrome and pseudoexfoliation syndrome) following previous full 360 degree 
SLT, who are recruited in an ongoing clinical trial entitled ‘A randomized clinical 
trial of laser trabeculoplasty (SLT) in open angle glaucoma who had been 
previously treated with complete SLT’. 
In section 3.1, a thorough description of the ongoing clinical trial is provided. 
Section 3.2 elaborates the decision model tree with calculation of ratios of success 
and failure of each intervention arm. Section 3.3 depicts the cost calculation of the 
trial components and in section 3.4, final analysis and measures are outlined. 
3.1 - Trial section 
3.1.1 - Ethics statement 
This RCT received approval from The University of Western Ontario Health 
Science Research Ethics Board (REB# - 103028).  
3.1.2 The Hypothesis and the Design of the Trial 
The trial hypothesis is that, SLT will be equivalent to ALT for laser treatment of 
open angle glaucoma. So, an active equivalence parallel armed randomized multi-
centered clinical trial based on the results of earlier clinical trial work with SLT 
and ALT was undertaken in an attempt to demonstrate expected equivalence 
between the two laser treatments SLT and ALT with respect to intraocular 
pressure lowering in patients who had previous full SLT. There is no indication 
that either laser modality would be superior to the other (Samples et al. 2011, 
Rolim de Moura et al. 2007, Shi and Jia 2013). Furthermore, both laser procedures 
are counted under the same OHIP code and the events of the post-laser clinical 
pathways between the two are same. In keeping with an “effectiveness” type 
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clinical trial, a generalizable study population, permissive eligibility criterion, an 
easily administered treatment protocol and outcomes that are relevant to patient 
care were chosen. Inclusion criteria are meant to admit a range of glaucoma 
patients as would be seen in the clinic – the results are explicitly meant to be 
generalizable to the broader glaucoma population eligible for repeat laser 
trabeculoplasty in western countries. 
When performing a hypothesis testing such as an active equivalence trial like this 
one, two types of basic error can occur namely type I and type II. Type I error 
occurs when we reject null hypothesis when it is true. For example, when a 
researcher claim based on his experiment and statistical analysis of data that, the 
experimental drug is effective in reducing the morbidity of a specific disease than 
the placebo, when, in fact, there is no such difference between them, a type I error 
has occurred. The probability of committing type I error is known as the level of 
significance, denoted by α. In practice, the standard type I error rate is 5% or 
α=0.05. Type II error occurs when null hypothesis is not rejected when it is false. 
When a researcher concludes that there is no difference between the experimental 
drug and the placebo in reducing the morbidity of a specific disease, but in fact, 
there is a difference. The probability of committing type II error is denoted as β. 
The power of a test, which is denoted as 1-β, is the ability to reject a null 
hypothesis when it is false. There is an inverse relationship between power and β. 
Increase of power requires a larger sample size (Chow and Liu, 2004). 
3.1.3 Trial Interventions 
The intervention is to apply one setting of complete SLT or one setting of 
complete ALT. On the day of laser trabeculoplasty, intraocular pressure is checked 
and one drop of 0.15% brimonidine is instilled in the study eye before and after 
laser treatment to decrease the chance of post-laser IOP spike at the one hour 
measuring point. Patients are then treated with either SLT or ALT according to the 
randomization schedule. 
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3.1.4 Study Center 
There are sites in London, Toronto, Hamilton, Edmonton, Calgary, Halifax and 
Montreal of Canada. The present study considers data from all sites.  
3.1.5 Randomization and Allocation  
The ophthalmologist assessed eligibility criteria and verbally explained the study 
to the potential patient. Once a patient has decided to participate, they are asked to 
sign the informed consent. Then they are randomized.  
At each center, a blocked randomization was performed to recruit participants 
alternately in order to force reasonably equal number of eyes in both treatment and 
control arms.  . The allocation schedule, done by computer (e.g. STATA, College 
Station Texas) from the conditional uniform distribution, is generated by the study 
coordinating center at the Ivey Eye Institute, University of Western Ontario with 
the help of the Lawson Research Kidney Research Unit, LHSC, London, Ontario.  
3.1.6 Treatment Masking 
The patient, not the clinician, is masked to intervention (either one complete 
setting of SLT or one complete setting of ALT). 
3.1.7 Inclusion and Exclusion Criteria 
Inclusion Criteria:  
1. Study base: From one of the practices participating in this study. 
2. More than or equal to 18 years of age. 
3. Open angle glaucoma, including ocular hypertension, pigmentary 
dispersion syndrome and pseudoexfoliation syndrome, as long as the angle 
is open, to increase the generalizability of the study.  
4. Previous 360 degree SLT (one time of 360 degree or two 180 degree).  
5. Intraocular pressure greater than 16 mm Hg on at least two consecutive 
occasions separated by one month. From previous SLT vs ALT clinical 
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work by Damj et al. (2006), mean IOP of diagnosed OAG patients for one 
year follow-up period was as low as 17.88 mmHg with a SD of 3.92.  
6. Two sighted eyes (best corrected visual acuity of 20/200 or better) 
7. Willing to participate after being informed and reading the patient 
information material that explains the study. 
Exclusion Criteria: 
1. Any evidence of secondary open angle glaucoma (other than pigmentary 
and pseudoexfoliation) or narrow angle glaucoma (where the anterior 
trabecular meshwork is not visible 360 degrees). As they would make the 
study population too heterogeneous.  
2. Advanced visual field defect in the eye being considered for treatment 
(defined as a scotoma within 10 degrees of fixation or split fixation on 
Humphrey's visual field 24-2, full threshold program) as they would be too 
close to central visual loss to be considered ethically feasible to include. 
3. Previous non laser glaucoma surgery in the eye being considered for 
treatment as this would change the angle architecture too unpredictably to 
be included. 
4. Intraocular surgery anticipated in the 12 months after treatment. 
5. Any corneal disease obscuring adequate visualization of the anterior 
chamber trabecular meshwork or reliable applanation tonometry. 
6. Present treatment with topical or systemic steroids or anticipated treatment 
with systemic steroids in the 6-months following treatment because of a 
high probability condition (such as giant cell arteritis or a collagen vascular 
disease) as steroids themselves had a pressure increasing effect in an 
unpredictable fashion. 
7. Previous ALT. 
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3.1.8 Starting medication status of patients 
Common treatment algorithms comprise the use of medication until failure 
followed by laser and finally incisional surgery. However, recent trends have 
shown an increasing proportion of physicians using laser first and avoiding the use 
of medications until necessary (Katz et al. 2012, Mcilraith et al. 2006). To reflect 
this changing clinical practice, this trial recruited patients regardless of medication 
status (except for steroids).  
3.1.9 Duration of Intervention 
The laser session for each group takes approximately 5 minutes. 
3.1.10 Baseline data, Frequency and Duration of Follow-Up 
After patients are screened for eligibility and provide their informed consent, 
baseline data (demographic variables and baseline IOP) are collected. There is a 
follow-up visit at 1-hour post-laser, and patients are prescribed topical steroid 
(1drops 4x/day). They are then evaluated at approximately the same time of day as 
the baseline examination (to minimize diurnal variation in pressure), at the end of 
week 1, and at 1, 3, 6 and 12 months post-operatively. At all follow-up 
examinations, the IOP, best corrected vision acuity, the anterior chamber reactions 
(cells/flare) are recorded. For this thesis, patients with 6-month follow -up data are 
considered.   
3.1.11 Primary and Secondary Outcomes  
The primary outcome for the clinical trial is the change in intraocular pressure 
from the baseline visit to the twelve-month visit (a continuous variable). The 
Goldman applanation tonometer, calibrated weekly, is used at approximately same 
time of the day (±1-hour) at baseline visit and during each follow-up. This thesis 
will use data obtained at 6 months. 
Secondary outcomes include, exclusion of pseudoexfoliation or pigment 
dispersion syndrome and repeating the primary analysis. Status of anterior 
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chamber inflammation (graded from 0 to +4, based on standard criteria), Snellen 
visual acuity (in LOGMAR units, a continuous variable), trabecular meshwork 
pigmentation (graded from 0 to + 4, an ordinal variable, compared to a standard 
photograph) and number of glaucoma medications needed per patient in each 
group are recorded at every post-operative visit for subgroup analysis.     
For this thesis, intraocular pressure change from the baseline visit to the follow-up 
visit up to 6-months have been considered. The effectiveness of each intervention 
(ALT and SLT) for outcomes (treatment success or failure) and relevant cost 
components of the laser treatment modalities have  been compiled and computed 
and a cost-effectiveness analysis of repeat laser treatment (ALT vs SLT) following 
at least one full previous SLT has been carried out. 
3.1.12 Sample size:  
In an active control equivalence trial, the formula for sample size for a continuous 
outcome for each group is: 
    N=2v2(Zα+Zß) 2 /d2  
                                                  (Chow and Lee, 2004Blackwater and Chang, 1984) 
         Where, N = Sample size for each group. 
  v2 = Variance of the continuous variable. 
  Zα= Type I error.             
  Zß= Type II error. 
  d2= The squared difference in the equivalence study that would be   
                             clinically meaningful.  
 v2: From previous SLT vs ALT clinical work (Damji et al. 2006), the 
standard deviation of the difference in IOP between the two groups at 
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different times varied between 3.4 and 5.8 mm Hg.  The median standard 
deviation from all pressures recorded was 5.0 mm Hg, which is used for v2. 
 
 Zα: This value is 1.96 for the standard acceptable type I error rate of 0.05, 
two sided test, in an active controlled equivalence trial.  
 
 Zß: To reduce the chance of a type II error, which is central to an 
equivalence study, 90% power is used. This value is therefore 1.282. 
 
 d2: A meaningful clinical difference (squared) that would change the 
management of OAG had been chosen to be 3 mm Hg by the expert group.   
 
As we have an active control group (ALT) and a comparator group (SLT), the 
total sample size (for both active control and comparator group) would be 
                                 2N=4v2(Zα+Zß) 2 /d2 
Plugging the value of the formula, the total sample size     
                                                 2N=4(5.0) 2 (1.96+1.282) 2 /32 
        2N=117 eyes. 
Assuming a 10% drop out rate would require to increase the sample size by (1-d) 
where d is 0.1 in this case. The sample size would be: 
                                                     2N=117/ (1 - 0.1)     
                                                           2N=130 eyes 
When cluster sampling would be done, the sample size estimate must be increased 
by the factor: 
 1 + (m-1)  
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 Where m = Average cluster size  
             = The intra-class correlation coefficient (Friedman et al. 1996).   
Based on previous work, it is estimated that 15% of individuals might be 
randomized from any one center from a cluster (Damjii et al. 2006).  With this 
assumption, the average cluster size is 1.15.  As the cluster would be within fairly 
homogenous practices, the  might be as high as 0.7.  If   = 0, then each 
individual in one clusters responds same as individual in any other cluster. If  = 
1, then all individuals in a cluster responds the same (Friedman et al. 1996).   
So adjustment factor 1 + (m-1)  = 1 + (.15)0.7 = 1.105.  
Multiplying this correction factor by 130 eyes resulted a final sample size of 144 
eyes. 
At the time of writing this thesis, a total of 91 eyes has completed the 6-month 
follow-up. In this study, analysis is based on this sample size (91 eyes). Based on 
this reduced sample size, the recalculated power of the study would be 81% 
instead of 90% (See Appendix C for details). 
3.1.13 Trial Management 
Data, recorded on a standardized form by the research assistant, are entered in a 
web based data uptake system, checked for completeness, errors and 
inconsistencies by the coordinating center at located at the clinical research unit, 
Ivey Eye Institute, University of Western Ontario. Any data discrepancy is fixed 
accordingly. A double data entry protocol, that require the data entry personnel to 
re-enter all data a second time using identical error verification parameters, is used  
to ensure data integrity and accuracy for all key variables. Patient confidentiality is 
guarded with stringent security procedures.  
The executive committee oversees all aspects of the trial. The Data Safety and 
Monitoring Committee (DSMC), independent of the trial functioning participants, 
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consists of two glaucoma expert physicians and one epidemiologist/biostatistician, 
with provision to invite ad hoc expert consultancies as required. The DSMC 
ensures that that study participants are not exposed to unnecessary or unreasonable 
risks and that the study is being conducted according to the highest scientific and 
ethical standards. Based on the review of both primary and secondary interim 
analysis, the DSMC has the right to recommend whether the study needs to be 
changed or terminated. In the event that the Study PI and/or the Executive 
Committee disagree with the DSMC recommendation to modify or to terminate 
the trial, a third party arbitrator from the University of Western Ontario Research 
Ethics Board, who possesses the knowledge and experience to make a final 
decision in the matter, will be called upon. 
3.2 Decision Tree Model  
For this thesis, a decision tree model was created using TreeAge Pro 2009 to 
represent the possible treatment outcome for a patient over a period of 6-month 
after intervention. Due to the short span of follow-up time and few treatment 
outcomes, this decision tree model would be sufficient to model the clinical 
scenario without the need of Markov modeling. 
The model was built using the data from the ongoing clinical trial cohort of adults 
aged 18 years or more suffering from uncontrolled open angle glaucoma patients 
(including ocular hypertension, pigmentary dispersion syndrome and 
pseudoexfoliation syndrome) with maximally tolerated medical therapy and at 
least one previous full SLT. The outcome of interest is the IOP lowering effect of 
each intervention. 
Our focus of interest was to evaluate the cost-effectiveness of   the laser treatments 
(SLT versus ALT) following previous full SLT based on the treatment outcome at 
6-month post -laser follow-up. 
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3.2.1 Structuring the decision tree model 
The overall structure was determined after consultation with ophthalmology 
experts by identifying possible clinical pathways of patients undergoing repeat 
laser trabeculoplasty. In our trial, patients underwent laser (either ALT or SLT). . 
Presence or absence of an IOP spike at 1-hour post-laser (defined as rise of IOP ≥ 
5 mm after 1-hourlaser intervention from baseline for this study) is considered a 
possibility consistent with previous published studies (Kara et al. 2013; Johnson et 
al. 2006; Nagar et al. 2005). Laser surgery might either be successful (using 
definitions in line with similar previous studies - either 3mmHg reduction in 
absolute intra ocular pressure from baseline or a reduction of ≥ 20% from baseline 
IOP at 6-month follow-up), in which case they would follow the initial normal 
standard of care (i.e. laser visit + 4 follow-up visits). Based on standard of care, it 
was decided that for the failure cases of the laser treatments at 6-month visit (v6), 
patients either would have another SLT (if IOP at v6 is <= 5 mm from baseline) or 
proceed to incisional surgery (if IOP at v6 > 5mm from baseline), which would 
add the costs of another SLT or surgery, respectively, and also cost of additional 4 
follow-up visits for each scenario.  
3.2.2 Societal and Ministry perspective of the decision model tree 
For societal perspective, data from all participants are included to calculate the 
ratio of outcome and IOP spike in the decision tree. For ministry perspective, only 
data from participants having age 65 years or more are considered. The reason 
being that all drug costs are covered by the ministry when patients are 65 years or 
older. Ideally, from societal perspective, indirect medical costs that may include 
wage loss, travel costs for treatment purposes, wage loss of accompanying persons 
etc., should be included in the cost analysis of any medical situation. However, 
indirect treatment cost has more impact in chronic disease of young population 
leading to disability and significant loss of economic contribution to the society. 
Disease like glaucoma, which mainly affects elderly population, comparatively 
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has less economic impact in terms of indirect medical cost. Moreover, laser 
treatments for glaucoma is a short outpatient medical procedure without any 
significant disastrous post-procedural adverse events. It does not need hospital 
admission. So for this specific study, exclusion of indirect medical cost would not 
have any substantial cost-impact that may affect the cost-effectiveness outcome. 
3.2.3 Calculation of success and failure ratio of each intervention for the 
decision tree model 
Based on the definition of success of treatment, ratio of success is calculated from 
the proportion of patients in each intervention arm with a successful outcome. The 
ratio of failure is calculated from (1-ratio of success). Success of treatment is 
defined as either 3mmHg reduction in absolute IOP from baseline IOP or a 
reduction of ≥20% from baseline IOP to follow-up visit at 6-month, as defined in 
the Manual of Procedure (MOP) of the clinical trial. Similar definition of success 
has also been used previously. (Akhtar 2014; Martow et al. 2011; Mao et al. 2008; 
Hodge et al. 2005). 
3.2.4 Determining effectiveness of each intervention  
Each intervention arm (ALT and SLT) is stratified based on outcome (success or 
failure) at 6-month post-intervention follow-up visit (v6). So there are a total of 4 
groups as follows: 
 ALT Success group 
 ALT failure group 
 SLT success group 
 SLT failure group 
For each group, baseline mean IOP and mean IOP reduction from baseline at 6-
month post-laser follow-up periods (v6) are determined. The effectiveness of ALT 
and SLT for each group is calculated considering the reduction of mean IOP at v6. 
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The following general formula is used: 
 Effectiveness of Intervention at v6 = (Mean IOP reduction at 
v6)/Mean Baseline IOP                 
Considering societal (all participants considered) and ministry perspective 
(participants aged 65 years and above), there are 2 separate decision model trees. 
Expected costs and effectiveness of each intervention are calculated from them. 
The incremental cost-effectiveness ratio (ICER) is calculated as the extra cost 
needed to lower one additional unit of IOP in mmHg from baseline for each 
decision model tree. 
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                                                                 Figure 5: Decision Tree Model of ALT and SLT intervention: Societal perspective 
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                                                 Figure 6: Decision Tree Model of ALT and SLT intervention: Ministry Perspective 
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3.2.5 Calculation of expected values of costs and effectiveness  
From the decision tree model of societal and ministry perspective, we have 
calculated the expected values of costs and effectiveness for both ALT and SLT 
interventions.  
3.2.6 Calculation of incremental cost-effectiveness ratios (ICERS) 
From the expected values of costs and effectiveness of ALT and SLT 
interventions, we have calculated the ICERs for reduction of 1 mmHg IOP from 
baseline at 6-month post-intervention period from both societal and ministry 
perspective. 
3.2.7 Willingness to pay (WTP) 
We compare ICERs from previous economic studies with similar clinical 
scenarios of treating OAG with IOP lowering medications for 6-month follow-up 
period. 
3.2.8 Sensitivity analysis 
Sensitivity analysis is an essential component of both decision tree and cost-
effectiveness analysis. It is a well-accepted, method to evaluate and address the 
uncertainty on the conclusion of a decision analysis (Petitti, 2000).    We consider 
IOP lowering effect of ALT and SLT intervention and Capital Cost of ALT and 
SLT to be potential drivers of the decision tree model for generating the expected 
values of costs and effectiveness for both ALT and SLT interventions. We would 
perform one way sensitivity analysis to investigate the extent to which the 
uncertainty of these variables would affect the decision model tree results. We 
would assign plausible ranges based on upper and lower 25% limits for the base 
case value. This would provide substantial evidence to address the uncertainty of 
base case ICERs value for both interventions (ALT vs SLT) from societal and 
ministry perspective. Moreover, the statistical and quasi-statistical methods (e.g., 
probability density function, the Bayesian approach) for estimating the uncertainty 
62 
 
of expected outcome from the decision analytic model has not been widely applied 
(Petitti, 2000).  
3.3 Calculation of intervention costs  
Many parts of costing of the trial had been calculated previously (Akhter, 2015). 
We have updated these costing as needed and calculated costing of new items. 
3.3.1 Calculation of direct costs 
Direct costs in health care problems are agreed generally as opportunity costs of 
formal health-care goods and services like hospital and nursing-home  care 
expenses, health care personnel fee schedules, drugs and so on (Ernst R, 2006). 
For this thesis, direct costs have been calculated considering charges of health care 
delivery personnel, procedural costs, post-operative medication costs and per-
patient capital costs of interventions.      
3.3.1.1 Physician time and follow-up schedule: 
It includes baseline assessment, 1laser intervention appointment and 5 scheduled 
follow-up visits of partial assessment and tonometry at one hour, one week and 1, 
3, and 6-month post-laser procedure. For failure cases at 6months, additional costs 
of either a repeat SLT or incisional surgery and 4 follow-up visits are added. 
For monetary valuation of unit cost, as nearly half the participants are from 
Ontario and fee schedules for similar services are nearly same across Canada, we 
use the OHIP fee schedule, in general as follows: 
 Laser visit: $205.55 (OHIP fee code: E134) 
 Follow-up visit: $34.05 (OHIP code A234-partial assessment $28.95 + 
OHIP code G435-tonometry $5.10). 
 Glaucoma filtration surgery: $550.00 (OHIP code E132) 
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3.3.1.2 Ophthalmic technician time and nurse time: 
An ophthalmic technician assists the ophthalmologist to perform tonometry and 
other examination procedures. Interviews with the trial ophthalmic technicians 
revealed that they spent an average of 40 minutes during the laser visit and 15 
minutes at each follow-up visit. The average wage of an ophthalmic technician is 
determined $30/hour. We took the information from St. Joseph's Health Care 
(SJHC), London, Ontario from payroll services of Healthcare Materials 
Management Services (HMMS). Unit cost for an ophthalmic technician is 
$0.50/min. 
For nurses, an average of 1-hour is necessary for laser intervention, and two nurses 
are required. The average hourly wedge of nurse time of $31/hour is obtained from 
HMMS. 
We assume that, these costs are similar across Canada. 
3.3.1.3 Capital costs: 
Capital costs are investments as an asset which is used over time (Drummond et 
al. 2015). Costs of equipment needed for the intervention using monetary values 
from the HMMS at SJHC are calculated. Capital cost is the same for each patient 
of the same arm. The following schema is used to calculate per patient capital cost 
(Drummond et al. 2015): 
 Per patient capital cost = 
((L+TR+EC+(SC*Y)+(LR*Y)+(MS*N*Y))/(N*Y) 
  Where, L=Laser 
  TR=Tube Replacement 
  EC=Exam chair 
  SC=Service Contract 
  LR=Annual Lens Replacement Cost 
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  MS= Medications/Supplies per Patient (includes tonometry cleaning  
            supplies, brimonidine drops, Gel for lens application) 
  N=Number of patients (Based on expert opinion) 
  Y=Laser lifetime in years 
 
Table 1: Capital cost calculation 
Item 
Cost for ALT 
(CAD) 
Cost for SLT 
(CAD) 
Laser 180,000 70,000 
Tube Replacement 25,000 N/A 
Exam chair 5,000 5,000 
Service Contract 8,800 5,085 
Lens Replacement per year 500 500 
Laser lifetime in years 8 8 
Medications/Supplies per Patient 1 1 
Number of patients 1000 500 
Per patient capital cost (Unit 
Cost) 
36.56 30.92 
 
3.3.1.4 Medications: 
As hospitals provided post-laser use of brimonidine, it is included in the capital 
cost. Maxidex eye drop (4x/day for 4 days) is prescribed for each patient post-laser 
($8.39 for 1 bottle of 5ml with 10% pharmacy mark up, included in direct cost).  
Baseline medications and their costs have not been considered for this thesis with 
the assumption that, appropriate randomization would result in a homogenous 
distribution of participants across the two intervention groups based on disease 
severity and baseline IOP lowering drug consumption (mean number of 
medications used in each group). 
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3.3.2 Costs not included: 
Other than the laser equipment, the cost of hospital infrastructures, overheads and 
buildings is not considered as they are difficult to assess and assigning them to the 
specific procedure usually results in irreducible capriciousness and sensitivity to 
methods (Tan et al. 2009, Finkler et al. 2007, Barnett, 2009).  
Indirect costs, often termed as direct non-health care costs, refers to productivity 
costs associated with lost or impaired ability of work or lost productivity due to 
death or disability (Neumann, 2009). This is more concern for a societal 
perspective. According to the Panel on Cost-Effectiveness Analysis of US Public 
Health Service, productivity costs should not be valued monetarily. It should be 
encompassed as health effects from the intervention (Gold et al. 1996). However, 
for highly disabling illness of young patients, exclusion of productivity costs from 
the numerator of CEA may have a large effect (Petitti, 2000).  As laser 
trabeculoplasty is an outpatient procedure, that usually does not require long term 
absence from normal daily tasks, wage loss due to the intervention procedure of 
patients and their accompanying personnel, where applicable, is ignored in this 
thesis. Travel costs are also not included assuming that, they would be similar in 
both intervention arms, thus nullifying each other and would not influence the 
CEA if not included.  
3.4 Final Analyses and measures 
Our main purpose is to perform a cost-effectiveness analysis for this thesis. 
Demographic characteristics of participants after stratification based on 
intervention arms are done. Expected costs on all decision model trees are 
performed and ICER for each decision model tree is calculated and compared. 
One way sensitivity analysis is done considering the IOP lowering effect and 
capital cost of ALT and SLT as the potential drivers for changes is expected cost 
of laser modalities. Treatment outcomes (success and failure) of both arms are 
presented considering different parameters.   
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Chapter 4 - Results 
4.1 Descriptive Statistics 
Data was available for 91 participants for a 6-month follow-up period, 46 in ALT 
arm and 45 in SLT arm. Mean age of ALT arm was slightly higher than SLT 
(69.28±8.72 vs 65.97±11.81). In both arms, number of male participants were 
slightly higher than females. More right eyes were treated in ALT group and for 
SLT group, it was reversed. Caucasian race ranked highest among both arms 
(82.6% in ALT vs 82.2%). (Table 2). 
Table 2: Descriptive statistics of participants 
Demographics ALT SLT 
Age(Yrs)±(SD) 69.28±8.72 65.97±11.81 
Male 28 25 
Female 18 20 
Treated Eye-Right (OD) 26 18 
Treated Eye- Left (OS) 20 27 
  Race/Ethnicity    
Caucasian 38 37 
African 4 2 
Asian 2 2 
Middle East  0 3 
Aboriginal 1 1 
Self-Defined 1 0 
 
4.2 Number of IOP lowering Medications at Baseline: 
The mean of number of IOP lowering medications at baseline for ALT group was 
1.22 (95% CI, 0.90 to 1.53) and for SLT group was 1.36 (95% CI, 0.97 to 1.74). 
(Table 3). 
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Table 3: Number of IOP lowering medications at baseline 
  Number of Medications       
Intervention 
Arm 
0 1 2 3 4 Mean 95% CI Total 
ALT 15 13 11 7 0 1.22 0.90, 1.53 46 
SLT 16 10 8 9 2 1.36 0.97, 1.74 45 
 
4.3 Baseline and Follow-up Mean IOP at different time point: 
Mean Baseline IOP for ALT and SLT arm were similar (21.65±4.08 vs 
22.13±4.21, respectively). ALT arm showed a steady decrease over 6-month 
duration. However, for SLT arm, there was a rise in Mean IOP at 6-month 
compared to IOP reduction at 3-month from baseline (19.11±4.29 vs 17.54±3.71, 
respectively). (Table 4). 
Table 4: Mean IOP (in mmHg) at baseline and different time points 
Timeline ALT SLT 
Baseline 21.65±4.08 (Min:12, Max:33) 22.13±4.21 (Min: 16, Max: 30) 
1-hour 14.76±4.83 (Min:5.5, Max:33.5) 15.86±5.17 (Min: 8, Max: 28) 
1-week 20.14±4.83(Min:11.5, Max:33) 17.92±4.27 (Min: 11.5, Max: 28.5) 
1-month 18.71±4.20(Min:11, Max:29) 17.43±3.91 (Min: 11, Max: 26) 
3-month 18.43±5.42(Min:6, Max:41) 17.54±3.71 (Min: 12, Max: 25.5) 
6-month 18.22±4.37(Min:9, Max:31) 19.11±4.29 (Min: 13.5, Max: 32) 
 
4.4 Mean IOP Reduction from Baseline at different time points: 
While ALT arm showed a steady and sustained reduction in IOP from baseline to 
6-month follow-up, SLT arm  demonstrated a more mean IOP reduction up to 3-
month follow-up than ALT arm, but at 6-month, had less  mean IOP reduction 
than ALT. (Table 5). 
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Table 5: Mean IOP reduction (in mmHg) from baseline at different time points 
Timeline ALT SLT 
Baseline 21.65±4.08  22.13±4.21  
1-week 1.51±3.88  4.22±4.42 
1-month 2.94±4.42 4.70±4.44 
3-month 3.22±5.44 4.59±3.80 
6-month 3.43±5.17 3.02±4.59 
4.5 Eyes achieving 20% IOP reduction from Baseline to different time 
points: 
ALT arm had gradual increase of number of eyes achieving 20% reduction of IOP 
from baseline for the 6-month time horizon. For SLT arm, up to 1-month, almost 
half of the eyes (48.8%) had achieved this, but at 3-month and 6-month follow-up, 
there was substantial drop (44.4% and 35.5%, respectively). (Table 6). 
Table 6: Eyes with 20% IOP reduction from baseline at different time points 
Timeline ALT (n=46) SLT (n=45) 
1-week 23.9% (11/46) 48.8% (22/45) 
1-month 39.1% (18/46) 48.8% (22/45) 
3-month 36.9%(17/46 ) 44.4% (20 /45) 
6-month 41.3% (19/46 ) 35.5% (16/45) 
4.6 Outcome of treatment (success or failure) at 6-month follow-up 
We defined success of treatment as either 20% reduction of IOP from baseline or 
absolute reduction of IOP of 3mmHg or more from baseline, or both. ALT arm 
had higher success outcome at 6-month follow-up. (Table 7). 
Table 7: Outcome of treatment at 6-month follow-up 
Outcome ALT (n=46) SLT (n=45) 
Success 58.7% (27/46) 42.2% (19/45) 
Failure 41.3% (19/46) 57.8% (26/45) 
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Majority of the patients in both arms had previous SLT done twice.  Only 1 
patient, in ALT arm, had previous SLT done three times. (Table 8). 
Table 8: Previous SLT history and outcome at 6-month follow-up 
          ALT (n=46)            SLT (n=45)   
Previous 
SLT Success Failure Success Failure 
Once 19.6% (9/46) 13.0% (6/46) 8.9% (4/45) 20.0% (9/45) 
Twice 39.1% (18/46) 26.1% (12/46) 33.3% (15/45) 37.8% (17/45) 
Thrice 0.0% (0/46) 2.2% (1/46) 0.0% (0/45 eyes) 0.0% (0/45) 
 
In ALT arm, 23 out of 38 eyes of Caucasians had successful outcome at 6-month, 
compared to 14 out of 37 eyes in SLT arm. (Table 9). 
Table 9: Outcome among race/ethnicity at 6-month follow-up 
Race/Ethnicity  ALT(Success/Failure) SLT (Success/Failure) 
 Caucasian 23/15 14/23 
African 1/3 1/1 
Asian 2/0 2/0 
 Middle East  0/0 2/1 
Aboriginal 1/0 0/1 
Self-Defined 0/1 0/0 
 
Only 1 patient in ALT arm had an IOP spike at 1-hour post-laser. (Table 10). 
Table 10: IOP Spike at 1-hour post-laser 
  ALT SLT 
IOP Spike 1 0 
No IOP Spike 45 45 
 
For failure cases at 6-month, either repeat SLT or surgery had been designed based 
on IOP of that visit. Repeat SLT was planned for patients with IOP 5 mmHg or 
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less from baseline. Surgery was planned for those having IOP greater than 5 
mmHg from baseline. ALT arm had a total of 19 failure cases and SLT arm had 
26. (Table 11). 
Table 11: Further treatment plan for failure cases at 6-month follow-up 
Treatment Plan ALT SLT 
Repeat SLT 16 24 
Surgery 3 2 
 
4.7: Obtaining Ratio of Treatment outcome for the Decision Model Tree  
4.7.1 Societal perspective 
For societal perspective, all data, irrespective of age were considered. Ratio for 
IOP spike at 1-hour post-laser for ALT and SLT group were 0.02 and 0, 
respectively and that for No IOP spike were 0.98 and 1, respectively. (Table 12). 
Table 12: One-hour post-laser IOP spike for ALT and SLT group: Societal 
perspective 
Intervention 
Arm 
IOP 
Spike 
No IOP 
Spike 
IOP Spike Ratio No IOP Spike Ratio 
ALT (n=46) 1 45 0.02 (1/46) 0.98 (45/46) 
SLT (n=45) 0 45 0 (0/45) 1 (45/45) 
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Success ratio of IOP spike and no IOP spike group at 6-month post-laser follow up 
for ALT arm were 0 and 0.6, respectively. (Table 13). 
Table 13: IOP Spike at 1-hour post-laser and treatment outcome at 6-month for 
ALT: Societal perspective 
Treatment 
Outcome 
IOP Spike at 1-hr post-laser IOP Spike  No IOP Spike   
At 6-month Yes (n=1) No (n=45) Outcome Ratio Outcome Ratio 
Success 0 27 0 (0/1) 0.6 (27/45) 
Failure 1 18 1 (1/1) 0.4(18/45) 
 
 
Success ratio of IOP spike and no IOP spike group at 6-month post-laser follow up 
for SLT arm were 0 and 0.42, respectively. (Table 14). 
Table 14: IOP Spike at 1-hour post-laser and treatment outcome at 6-month for 
SLT group: Societal perspective 
Treatment 
Outcome 
IOP Spike at 1-hr post-laser IOP Spike  No IOP Spike   
At 6-month Yes (n=0) No (n=45) Outcome Ratio Outcome Ratio 
Success 0 19 0  0.42 (19/45) 
Failure 0 26 0  0.58 (26/45) 
 
For 19 failure cases of ALT, the ratio of repeat SLT and surgery for IOP spike 
group were 0 and 1, respectively and for no IOP spike group were 0.89 and 0.11, 
respectively. (Table 15). 
Table 15: Treatment (Rx) plan for failure cases (at 6-month follow-up) of ALT 
group: Societal perspective 
Future Rx Plan IOP Spike at 1-hr post-laser  IOP Spike  No IOP Spike   
for Failure Cases Yes (n=1) No (n=18) Outcome Ratio Outcome Ratio 
Repeat SLT 0 16 0 (0/1) 0.89 (16/18) 
Surgery 1 2 1 (1/1) 0.11 (2/18) 
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For 26 failure cases of SLT, there was no case in IOP spike group. For no IOP 
spike group, ratio of repeat SLT and surgery were 0.92 and 0.08, respectively. 
(Table 16). 
Table 16: Treatment (Rx) plan for failure cases (at 6-month follow-up) of SLT 
group: Societal perspective 
Future Rx Plan IOP Spike at 1-hr post-laser  IOP Spike  No IOP Spike   
for Failure Cases Yes (n=0) No (n=26) Outcome Ratio Outcome Ratio 
Repeat SLT 0 24 0 0.92 (24/26) 
Surgery 0 2 0 0.08 (2/26) 
 
4.7.2 Ministry Perspective 
For ministry perspective, data from participants aged greater than or equal to 65 
years were considered. Ratio for IOP spike at 1-hour post-laser for ALT and SLT 
arms were 0.03 and 0, respectively and that for No IOP spike group were 0.97 and 
1, respectively. (Table 17). 
Table 17: One hour post-laser IOP spike for ALT and SLT group: Ministry 
perspective 
Intervention 
Arm 
IOP 
Spike 
No IOP 
Spike 
IOP Spike Ratio No IOP Spike Ratio 
ALT (n=33) 1 32 0.03 (1/33) 0.97 (32/33) 
SLT (n=24) 0 24 0 (0/24) 1 (24/24) 
 
Success ratio of IOP spike and no IOP spike at 6-month post laser follow up for 
ALT arm was 0 and 0.59, respectively and that of failure group were 1 and 0.41, 
respectively. (Table 18). 
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Table 18: IOP Spike at 1-hour post-laser and treatment outcome at 6-month for 
ALT group: Ministry perspective 
Treatment 
Outcome 
IOP Spike at 1-hr post-laser IOP Spike  No IOP Spike   
At 6-month Yes (n=1) No (n=32) Outcome Ratio Outcome Ratio 
Success 0 19 0 (0/1) 0.59 (19/32) 
Failure 1 13 1 (1/1) 0.41(13/32) 
 
 
Success ratio of IOP spike and no IOP spike at 6-month post laser follow up for 
SLT arm were 0 and 0.42, respectively and that of failure group were 0 and 0.58, 
respectively. (Table 19). 
Table 19: IOP spike at 1-hour post-laser and treatment outcome at 6-month for SLT 
group: Ministry perspective 
Treatment 
Outcome 
IOP Spike at 1-hr post-laser IOP Spike  No IOP Spike   
At 6-month Yes (n=0) No (n=24) Outcome Ratio Outcome Ratio 
Success 0 10 0  0.42 (10/24) 
Failure 0 14 0  0.58 (14/24) 
 
For 14 failure cases of ALT arm, the ratio of repeat SLT and surgery for IOP spike 
group were 0 and 1, respectively and for no IOP spike group were 0.85 and 0.15, 
respectively. (Table 20).  
Table 20: Treatment plan for failure cases (at 6-month follow-up) of ALT group: 
Ministry perspective 
Future Treatment 
Plan 
IOP Spike at 1-hr post-laser  IOP Spike  No IOP Spike   
for Failure Cases Yes (n=1) No (n=13) Outcome Ratio Outcome Ratio 
Repeat SLT 0 11 0 (0/1) 0.85 (11/13) 
Surgery 1 2 1 (1/1) 0.15 (2/13) 
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For 14 failure cases of SLT arm, there was no case in IOP spike group and for no 
IOP spike group, ratio of repeat SLT and surgery were 0.93 and 0.07, respectively. 
(Table 21). 
Table 21: Treatment plan for failure cases (at 6-month follow-up) of SLT group: 
Ministry perspective 
Future Treatment 
Plan 
IOP Spike at 1-hr post-laser  IOP Spike  No IOP Spike   
for Failure Cases Yes (n=0) No (n=14) Outcome Ratio Outcome Ratio 
Repeat SLT 0 13 0 0.93 (13/14) 
Surgery 0 1 0 0.07 (2/26) 
 
4.8 Cost of the intervention arms 
Capital cost of ALT and SLT per patient were 36.56 and 30.92 CAD, respectively. 
Health personnel charges and drug costs were included in the costing. (Table 22). 
Table 22: Cost-Calculations of the interventions 
Item  Cost (In Canadian Dollar) 
ALT Capital (Per Patient) 36.56 
SLT Capital (Per Patient) 30.92 
Maxidex Eye drop with 10% pharmacy mark up 9.23 
Laser Charge for Ophthalmologist 205.55 
Laser Charge for Technician 20.00 
Surgery Charge for Ophthalmologist 550.00 
Surgery Charge for Nurse 70.00 
Follow-up Charge for Ophthalmologist 34.05 
Follow-up Charge for Technician 7.50 
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4.9 Mean IOP reduction at 6-Month Follow-up 
4.9.1 Societal perspective: 
Mean IOP reduction of ALT and SLT arms from the societal perspective were 
3.435 mmHg (95% CI: 1.898 to 4.971) and 3.027 mmHg (95% CI: 1.648 to 4.405) 
from baseline. This difference was not statistically significant (p=0.69).  
(Table 23). 
Table 23: Baseline IOP and IOP reduction at 6-month: Societal perspective 
Intervention Arm n Mean IOP reduction at 6-month 95% CI 
ALT 46 3.435 1.898, 4.971 
SLT 45 3.027 1.648, 4.405 
*p-Value   0.69   
*By non-paired t-test   
 
4.9.2 Ministry Perspective: 
Mean IOP reduction of ALT and SLT arms from the ministry perspective were 
3.697 mmHg and 2.883 mmHg from baseline. This difference was not statistically 
significant (p=0.56). (Table 24). 
Table 24: Baseline IOP and IOP reduction at 6-month: Ministry perspective 
Intervention Arm n Mean IOP reduction at 6-month 95% CI 
ALT 33 3.697 1.649, 5.744 
SLT 24 2.883 0.926, 4.841 
*p-Value   0.56   
*By non-paired t-test   
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4.10 Determination of Effectiveness for Intervention Arms 
4.10.1 Societal perspective 
IOP lowering effectiveness for each success and failure group for ALT and SLT 
arms were calculated for societal perspectives. For failure group, effectiveness 
were negative. Success group of both arms had higher Baseline IOP. (Table 25). 
Table 25: IOP lowering effectiveness at 6-month follow-up for ALT and SLT: 
Societal perspective 
Intervention 
Arm 
Outcome of 
Intervention 
at 6-month 
Follow-Up 
 (n) 
Baseline 
Mean IOP  
Mean IOP 
reduction from 
Baseline at 6-
month Follow-
Up (v6) 
Effectiveness: Mean 
IOP reduction at v6 
from Baseline / 
Mean Baseline IOP  
ALT ALT Success 27 22.741 6.574 0.289 
ALT ALT Failure 19 20.105 -1.026 -0.051 
SLT SLT Success 19 24.421 7.263 0.297 
SLT SLT Failure 26 20.461 -0.069 -0.003 
 
4.10.2 Ministry Perspective 
IOP lowering effectiveness for each success and failure group for ALT and SLT 
arms were calculated for ministry perspective also and revealed similar results as 
that of societal perspective. (Table 26). 
Table 26: IOP lowering effectiveness at 6-month follow-up (v6) for ALT and SLT 
group: Ministry perspective 
Intervention 
Arm 
Outcome of 
Intervention 
at 6-month 
Follow-Up 
 (n) 
Baseline 
mean 
IOP  
Mean IOP 
reduction from 
Baseline at 6-
month (v6) 
Effectiveness: Mean 
IOP reduction at v6 
from Baseline / Mean  
Baseline IOP 
ALT ALT Success 19 23.263 7.263 0.312 
ALT ALT Failure 14 20 -1.143 -0.057 
SLT SLT Success 10 23.7 7.2 0.304 
SLT SLT Failure 14 21.5 -0.199 -0.009 
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4.11 Expected Values (Cost/Effectiveness) from the Decision Model Tree  
4.11.1 Societal perspective 
From societal perspective, the expected value of cost and effectiveness derived 
from the decision tree model for ALT arm was CAD 458/0.149 mmHg of IOP 
reduction from baseline IOP and that for SLT arm was CAD 448/0.123 mmHg of 
IOP reduction from baseline IOP. (Figure 9).
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Figure 7: Expected Values of Cost/Effectiveness from Decision Model Tree: Societal perspective 
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4.11.2 Ministry Perspective 
From ministry perspective, the expected value of cost and effectiveness derived from the decision tree model for 
ALT arm was CAD 467/0.154 mmHg of IOP reduction from baseline IOP and that for SLT arm was CAD 446/0.122 
mmHg of IOP reduction from baseline IOP. (Figure 10)
 
Figure 8: Expected Values of Cost/Effectiveness from Decision Model Tree: Ministry Perspective 
 80 
 
4.12: Incremental Cost-Effectiveness Ratio (ICER)   
4.12.1 Societal perspective 
Effectiveness of both treatment arms was calculated based on reduction of IOP by 
each intervention from the societal perspective (all age included). Effectiveness 
was calculated as an average of mean IOP reduction at 6-month post-laser follow-
up from mean baseline IOP. No strategies were clearly dominated by any other. 
Cost-Effectiveness (C/E) ratio for SLT was 3645.03 and that for ALT was 
3072.65. To switch from SLT to ALT, It would cost $ 356.49 for each extra unit 
IOP reduction. (Table 27). 
Table 27: CEA of ALT vs SLT, base case: Societal perspective 
Strategy Cost 
Incremental 
cost  
Effectiveness 
at 6-month 
follow-up 
Incremental 
effectiveness C/E 
Incremental 
C/E (ICER) 
SLT 448.34  0.123  3645.03  
ALT 457.58 9.24 0.149 0.026 3072.65 356.49 
 
 
Figure 9: Cost-Effectiveness graph from the societal perspective 
The cost-effectiveness graph from the societal perspective with cost on y-axis and 
effectiveness on x-axis showing none of the interventions were clearly dominated 
by any other, denoted by joining the ALT and SLT legend by a straight line. 
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4.12.2 Ministry Perspective 
For ministry perspective, the same effectiveness as that of societal perspective for 
each corresponding group was used. Participants aged ≥ 65 years were considered. 
The results were similar as that of societal perspective with different values. To 
switch from SLT to ALT, It would cost $ 649.71 for each extra unit IOP reduction. 
(Table 28). 
Table 28: CEA of ALT vs SLT, base case: Ministry perspective 
 
Strategy Cost 
Incremental 
Cost 
Effectiveness 
at 6-month 
follow-up 
Incremental 
Effectiveness C/E 
Incremental 
C/E (ICER) 
SLT 446.28  0.122  3644.32  
ALT 466.89 20.61 0.154 0.032 3028.25 649.71 
 
 
Figure 10: Cost-Effectiveness graph from ministry perspective 
Cost-Effectiveness graph from ministry perspective with cost on y-axis and 
effectiveness on x-axis showing none of the interventions were clearly dominated 
by any other denoted by joining the ALT and SLT legend by a straight line. 
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4.13 Sensitivity Analysis  
IOP lowering effectiveness and capital cost of ALT and SLT were considered as 
potential drivers of the decision model tree and the resultant ICERs. A one-way 
sensitivity analysis with 25% above and below value of base case variables with 4 
equal intervals in between were used for both societal and ministry perspective. 
4.13.1 One-Way Sensitivity analysis of Effectiveness: Societal perspective 
A 25% lowering of ALT Success Effectiveness and 25% increase of SLT Success 
Effectiveness results in dominance of SLT over ALT. (Table 29). 
Table 29: Sensitivity analysis of effectiveness value: Societal perspective 
  ICER   
Group 
Variable 
25% lower from Base 
Case 
25% higher from 
Base Case 
Dominance of Strategy 
ALT 
Success 
ALT is dominated by 
SLT 
135.38 
ALT is dominated by 
SLT when base case 
value is lowered by 
25% 
ALT 
Failure 
449.34 295.44 None 
SLT 
Success 
162.11 
ALT is dominated by 
SLT 
ALT is dominated by 
SLT when base case 
value is increased by 
25% 
SLT 
Failure 
348.69 356.49 None 
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Figure 11: One-Way Sensitivity analysis of Effectiveness: Societal perspective 
The horizontal axis of the graphs represent the effectiveness value, with base case 
value in the middle. The vertical axis is the incremental cost-effectiveness ratio 
(ICER). 
4.13.2 One-Way Sensitivity analysis of Capital Cost: Societal perspective 
One way sensitivity analysis of capital cost of ALT and SLT revealed that, none of 
the strategies were clearly dominated by any other.   
Table 30: Sensitivity analysis of capital cost value from societal perspective 
  ICER   
Group 
Variable 
25% lower from Base Case 25% higher from Base Case 
Dominance of 
Strategy 
ALT Capital 149.15 563.83 None 
SLT Capital 536.83 176.15 None 
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Figure 12: One-Way Sensitivity analysis of Capital Cost: Societal perspective 
The horizontal axis of the graphs represent the capital cost value, with base case 
value in the middle. The vertical axis is the incremental cost-effectiveness ratio 
(ICER). 
4.13.3 One-Way Sensitivity analysis of Effectiveness: Ministry Perspective 
A 25% lowering of ALT Success Effectiveness and 25% increase of SLT Success 
Effectiveness results in dominance of SLT over ALT. 
Table 31: Sensitivity analysis of effectiveness value: Ministry perspective 
  ICER   
Group 
Variable 
25% lower from Base 
Case 
25% higher from Base 
Case 
Dominance of 
Strategy 
ALT 
Success 
ALT is dominated by 
SLT 
269.89 
ALT is dominated by 
SLT when base case 
value is lowered by 
25% 
ALT 
Failure 
800.91 546.54 
None 
SLT 
Success 
323.83 
ALT is dominated by 
SLT  
ALT is dominated by 
SLT when base case 
value is increased by 
25% 
SLT 
Failure 
615.92 674.37 None 
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Figure 13: One-Way Sensitivity analysis of Effectiveness: Ministry perspective 
The horizontal axis of the graphs represent the effectiveness value, with base case 
value in the middle. The vertical axis is the incremental cost-effectiveness ratio 
(ICER). 
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4.13.4 One-Way Sensitivity analysis of Capital Cost: Ministry Perspective 
One way sensitivity analysis of capital cost of ALT and SLT revealed that, none of 
the strategies were clearly dominated by any other. (Table 32; See Appendix A for 
details).   
Table 32: Sensitivity analysis of capital cost value: Ministry perspective 
  ICER   
Group 
Variable 
25% lower from Base 
Case 
25% higher from Base 
Case 
Dominance of 
Strategy 
ALT 
Capital 484.8 814.62 
None 
SLT 
Capital 801.14 498.28 
None 
  
 
Figure 14: One-Way Sensitivity analysis of Capital Cost: Ministry Perspective 
 
The horizontal axis of the graphs represent the capital cost value, with base case 
value in the middle. The vertical axis is the incremental cost-effectiveness ratio 
(ICER). 
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Chapter 5:  Discussion 
5.1 Results 
In this thesis, the primary objective was to compute and compare  the cost-
effectiveness of two laser treatment modalities for uncontrolled open angle 
glaucoma (OAG) patients (including ocular hypertension, pigmentary dispersion 
syndrome and pseudoexfoliation syndrome) with at least one full previous SLT 
who were enrolled in an ongoing, active, equivalence parallel armed randomized 
multi-centered clinical trial entitled ‘A randomized clinical trial of selective laser 
trabeculoplasty (SLT) in open angle glaucoma who had been previously treated 
with complete SLT’. Data from those patients who completed a 6-month post-laser 
follow-up (a total of 91 cases) were included in the analysis. Both societal and 
ministry perspective had been considered for the analysis. For societal perspective, 
all patients were considered. For ministry perspective, patients aged ≥ 65 years 
had been considered only. All analyses were done by comparing the intervention 
arms (ALT versus SLT). Based on the treatment outcome at 6-month post-
intervention follow-up (either success or failure of treatment), two decision model 
trees, one for each perspective (societal and ministry), were developed. Ratio of 
IOP spike in mmHg at 1-hour post-laser was included in both the decision model 
trees. Weinreb et al. (1983) reported progression of visual field (VF) loss in 
advanced glaucoma patient experiencing post-laser IOP spike. IOP in the early 
post-procedural period might be a good predictor of treatment outcome (Downes 
et al. 1994). Reductions of mean IOP in mmHg from baseline to 6-month post-
intervention follow-up for both treatment outcomes for each intervention arm were 
calculated and used in the cost-effectiveness analysis as the effectiveness of 
corresponding outcome of intervention arm (i.e, ALT Success Effectiveness, ALT 
Failure Effectiveness, SLT Success Effectiveness, SLT Failure Effectiveness). For 
this thesis, the treatment success was defined as a reduction of IOP of 3mmHg or 
20% reduction or both from baseline at 6-month post-intervention follow-up. The 
MOP of the running clinical trial and previous studies on IOP reduction of OAG 
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used either or both of the conditions as a treatment success (Akhtar 2014; Martow 
et al. 2011; Mao et al. 2008; Hodge et al. 2005).  For cost-effectiveness analysis 
(CEA), expected value of cost and effectiveness were determined from the 
decision model tree from both societal and ministry perspective, and incremental 
cost effectiveness ratios (ICERs) were determined. The expected value of 
individualized care in cost-effectiveness analysis and decision making is a useful 
tool to identify opportunity to improvement of efficiency in health care (van 
Gestel et al. 2012). A one-way sensitivity analysis for effectiveness value and 
capital cost for both intervention arms and perspectives were performed using a 
range of 25% above and below the base case value with 4 equal intervals in 
between. Due to the short horizon of follow-up, discounting was not considered 
for CEA. The impact of IOP reduction on quality of life (improved or not) would 
not have been apparent for this follow-up period and therefore was not an analysis 
option. So, willingness to pay by the patients for ALT and SLT treatment 
strategies was not considered for this scenario. 
5.1.1 Clinical Trial Cohort 
Baseline demographic characteristics were comparable between ALT and SLT 
intervention arm. The mean age of clinical trial cohort for both ALT and SLT 
groups were above 65 years, reflecting the natural progressive deterioration and 
chronicity of OAG. Symptoms affecting visual field, including visual loss, 
generally start at age 65 years and up (Access Economics Pty Limited). Most of 
the patients were Caucasians. Mean baseline IOP for both intervention arms were 
quite close (2.2% higher in SLT arm). While SLT group showed a steady and 
higher reduction of IOP for the first three month compared to ALT group, the 
scenario reversed back in favor of ALT at 6-month post-laser follow-up. At that 
time, 58.7% eyes of ALT arm achieved successful outcome and for SLT arm, it 
was 42.2%. 
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5.1.2 Use of IOP lowering medications at baseline: 
Among 91 participants, a total of 60 participants were on 1 or more IOP lowering 
medications. The mean number of medications for ALT group was 1.22 (95% CI: 
0.90 to 1.53) and for SLT it was 1.36 (95% CI: 0.97 to 1.74). This very close 
approximation of two means (of number of medications) represent a proxy for 
homogeneous distribution of severity of disease across the randomized group. This 
also rationalized the exclusion of medication costs used at baseline for the cost-
effectiveness analysis. 
5.1.3 Costing Aspects 
For calculation of cost, we considered the charges of health care delivery 
personnel, procedural costs, post-operative medication costs and per-patient 
capital costs of interventions as direct costs, as these were the core costing for 
performing laser treatments for OAG. The costs of hospital infrastructures, 
overheads and buildings were not considered as they were difficult to assess and 
assigning them to the specific procedure like laser therapy for OAG in a hospital 
setting might cause much variability and sensitivity to methods and results (Tan et 
al. 2009; Finkler et al. 2007; Barnett, 2009). We also did not consider indirect cost 
such as wage loss due to the intervention procedure of patients and their 
accompanying personnel, as both ALT and SLT   were outpatient procedure that 
neither required long time absence from normal daily tasks nor in-patient care. We 
assumed that, this indirect cost would have an unsubstantial impact on cost 
outcome. Travel cost was also not considered with the assumption of similar 
expense in both intervention arms as an effect of proper randomization and thus 
would have a minimal impact, if at all, in the cost outcome. The per patient capital 
cost of ALT and SLT intervention groups were $36.56 and $30.92, respectively. 
5.1.4 Effectiveness Aspects and IOP reduction at 6-month follow-up 
Laser treatment modalities for OAG were intended to reduce the pre-treatment 
IOP to a target level. So the reduction of post-laser IOP from baseline to 6-month 
 90 
 
follow-up visit had been considered as an effectiveness of ALT and SLT 
intervention arms for this thesis. Effectiveness had been determined for both 
societal and ministry perspective. From societal perspective, the effectiveness of 
IOP reduction from baseline for SLT success group was slightly higher than 
corresponding ALT group (0.297 mmHg versus 0.289 mmHg). They remained 
similar for failure group also (SLT: -0.003 mmHg, ALT: -0.051 mmHg). For the 
ministry perspective, effectiveness of success and failure of ALT were higher than 
their SLT counterpart (ALT Success: 0.312 mmHg, SLT Success: 0.304 mmHg; 
ALT Failure: -0.057 mmHg and SLT Failure: -0.009). From societal perspective, 
expected value of effectiveness of ALT intervention was 0.149 mmHg and for 
SLT intervention, it was 0.123 mmHg. From the ministry perspective, expected 
effectiveness for ALT and SLT group were 0.154 mmHg and 0.122 mmHg, 
respectively. The effectiveness of both intervention arms remained close to each 
other.  
The difference of mean IOP reduction at 6-month post-laser follow-up for both 
intervention arms from both societal and ministry perspectives were not significant 
statistically. 
5.1.5 Cost-Effectiveness Analysis (CEA) and Incremental Cost Effectiveness 
Ratio (ICER): Societal perspective 
The expected cost and effectiveness of ALT and SLT from the constructed 
decision model tree were used to determine which laser modality was cost-
effective at 6-month post-laser follow-up from societal perspective. None of the 
interventions were clearly dominated by any other. Expected cost of ALT was a 
little higher than SLT ($458 versus $448, respectively) and so as the effectiveness 
(0.149 mmHg versus 0.123 mmHg).  ALT strategy was slightly costly and slightly 
more effective compared to SLT. To switch from SLT to ALT, it would cost 
$356.49 for each extra unit IOP reduction. 
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 5.1.6 Cost-Effectiveness Analysis (CEA) and Incremental Cost Effectiveness 
Ratio (ICER): Ministry Perspective 
The Ministry perspective also revealed similar results as that of societal 
perspective with different values. Expected cost of ALT was higher than SLT 
($467 versus $446, respectively) and so as the effectiveness (0.154 mmHg versus 
0.122 mmHg). Expected cost and effectiveness of SLT from societal and ministry 
perspective were almost close to each other; whereas they were a little higher for 
ALT from ministry perspective. Cost-Effectiveness(C/E) ratio of SLT was 
3644.32 and that for ALT was 3028.25. To switch from SLT to ALT, it would cost 
$ 649.71 for each extra unit IOP reduction. 
5.1.7 Sensitivity Analysis: Societal perspective 
For effectiveness variables, a 25% lowering of ALT Success Effectiveness and 
25% increase of SLT Success Effectiveness results in dominance of SLT over 
ALT. No other variables show any clear dominance to each other.   
Varying capital costs also revealed similar results as that of base case analysis. 
None of the interventions were clearly dominated by any other.  
5.1.8 Sensitivity Analysis: Ministry Perspective 
One-way sensitivity analysis from the ministry perspective, , also produced similar 
results as that of societal perspective. A 25% lowering of ALT Success 
Effectiveness and 25% increase of SLT Success Effectiveness results in 
dominance of SLT over ALT. Other variables did not show any clear dominance 
upon each other.  
Sensitivity analysis of capital costs also revealed similar results as that of base 
case for ministry perspective with no clear dominance of the interventions by any 
other.  
5.1.9 Willingness to pay for 1mmHg reduction of IOP: ICERs from other IOP 
lowering agents in similar scenario: 
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Lachaine et al. (2008) conducted a cost-effectiveness analysis of prostaglandin 
analogues for ophthalmic use. They did a systematic literature searches and 
conducted this CEA study from ministry perspective by using a decision analytic 
model considering PGAs with other comparative IOP lowering agents as first line 
of treatment and for both eyes assuming a 100% patient compliance. Costs were 
calculated from Ontario sources. Effectiveness was defined as reduction of IOP 
from at six month from baseline. For a six month duration of treatment, they 
calculated the ICER. When comparing Timolol with Latanoprost,   Latanoprost 
was costly and more effective than Timolol and the ICER was 81.80 dollars. 
When comparing Timolol with Travoprost,     Travoprost was costly & more 
effective than Timolol & ICER was 110.61 dollars.  These ICERs for reduction of 
1 additional mm Hg of IOP are much less than our calculated ICERs. In other 
words, Willingness to pay for 1mmHg reduction of IOP is much less than our 
calculated ICER. (Table 33). 
 
Table 33: Cost-effectiveness analysis of prostaglandin analogues for ophthalmic use 
 Strategy Cost   
(C) 
Incremental 
Cost 
IOP 
reduction at 
6-month (E) 
Incremental 
IOP 
reduction 
C/E Incremental 
C/E (ICER) 
Timolol 112.52 
 
6.31 
 
17.84 
 
Latanoprost 200.37 87.85 7.38 1.07 27.15 81.80 
VS 
Timolol 112.38 
 
6.73 
 
16.69 
 
Travoprost 191.64 79.26 7.45 0.72 25.73 110.61 
 
5.2 Strengths of the Study 
The major strength of this study is its active equivalence parallel armed 
randomized, single blinded, multi-centered clinical trial to assess the effectiveness 
of ALT and SLT in terms of IOP reduction from baseline. The study protocol 
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included a generalizable study population, permissive eligibility criteria, an easily 
administered treatment protocol and outcomes that are almost the same compared 
to regular care of such patients across Canada. One of the major criticisms of 
clinical trial based cost-effectiveness analysis is the application of rigorous 
protocol that might not be compatible with regular health care delivery for similar 
patients, especially may compliance could have been compromised in regular 
patient care and the costing might not reflect the real scenario (Drummond et al. 
2015). This study design diminished  these criticisms due to the very short single 
treatment protocol, where compliance is 100% guaranteed and use of regular 
patient care set-up for trial patients, the cost of which is a true mirror image of 
direct patient care costing in a regular hospital out-patient or ophthalmological 
health care delivery center. 
5.3 Limitations of the study 
The study has several limitations. The sample size used for this thesis is less than 
the calculated sample size (91 instead of 144 eyes) of the trial, so the power of the 
study was reduced. The 6-month follow-up outcomes may vary when one year or 
more follow-up period would be considered. In that case, cost-effectiveness 
analysis of the intervention arms may yield different results. Although it was 
assumed that, indirect cost of treatment would not have a substantial impact on 
cost calculation, it would bolster any cost-effectiveness analysis, especially for 
societal perspective, if authentic data of indirect treatment costs could be collected 
from the patients.  
 
5.4 Conclusion 
Our study result revealed that, for a 6-month post-intervention follow-up for 
uncontrolled glaucoma patients who have had at least one previous full SLT, 
neither ALT nor SLT strategies were clearly dominated by any other. ALT is 
slightly more effective and slightly costly over SLT strategy. To switch from SLT 
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to ALT, it would cost $ 356.49 for each extra unit IOP reduction from societal 
perspective and from ministry perspective, the same would cost $ 649.71. This 
ICERs were much higher in comparison to ICERS of other IOP lowering 
strategies in similar situations.  Sensitivity analysis with effectiveness variables 
showed dominance of SLT over ALT for some instance. SLT has the theoretical 
plausibility of repeatability and it is also easier to perform than ALT. All these 
factors should be considered when opting between ALT and SLT strategies for 
treatment of open angle glaucoma in patients having previous full SLT treatment. 
5.5 Implication of Study Results and Future Direction 
Our study provides information regarding the cost-effectiveness of SLT versus 
ALT in uncontrolled OAG patients previously treated with full SLT. As none of 
the alternatives were a dominant strategy at 6-month post-laser follow-up, and the 
cost and effectiveness of both strategies do not differ greatly, either options could 
be opted by the treating ophthalmologist considering the CEA. ALT is slightly 
more effective and also slightly costly. SLT has theoretical advantage of 
repeatability and its application is easy than that of ALT. A long term follow-up 
study with additional authentic information on indirect treatment costs from the 
patients in the future may provide more convincing cost-effective analysis 
information. It will help both the health policy makers and health care providers to 
choose between SLT and ALT treatment strategies with more confidence for the 
betterment of open angle glaucoma patients.  
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Appendix 
Appendix A: One-way Sensitivity Analysis Table 
Appendix A1: ALT Effect Success Sensitivity: Societal Perspective 
ALT 
Effect 
Success Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr C/E 
(ICER) 
0.217 SLT 448  0.123  3645.03  
 ALT 458  0.107  4293.13 (Dominated) 
        
0.253 SLT 448  0.123  3645.03  
 ALT 458 9 0.128 0.005 3581.77 1944.49 
        
0.289 SLT 448  0.123  3645.03  
 ALT 458 9 0.149 0.026 3072.65 356.49 
        
0.325 SLT 448  0.123  3645.03  
 ALT 458 9 0.17 0.047 2690.25 196.23 
        
0.361 SLT 448  0.123  3645.03  
  ALT 458 9 0.191 0.068 2392.49 135.38 
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Appendix A2: ALT Effect Failure Sensitivity: Societal Perspective 
ALT 
Effect 
Failure Strategy Cost 
Incr 
Cost Eff Incr Eff C/E 
Incr C/E 
(ICER) 
-0.064 SLT 448  0.123  3645.03  
 ALT 458 9 0.144 0.021 3187.28 449.34 
        
-0.0575 SLT 448  0.123  3645.03  
 ALT 458 9 0.146 0.023 3128.92 397.57 
        
-0.051 SLT 448  0.123  3645.03  
 ALT 458 9 0.149 0.026 3072.65 356.49 
        
-0.0445 SLT 448  0.123  3645.03  
 ALT 458 9 0.152 0.029 3018.37 323.11 
        
-0.038 SLT 448  0.123  3645.03  
  ALT 458 9 0.154 0.031 2965.98 295.44 
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Appendix A3: SLT Effect Success Sensitivity: Societal Perspective 
SLT 
Effect 
Success Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr C/E 
(ICER) 
0.223 SLT $448   0.092  4,877.49   
 ALT $458  $9  0.149 0.057 3,072.65  162.11  
        
0.26025 SLT $448   0.108  4,168.07   
 ALT $458  $9  0.149 0.041 3,072.65  223.44  
        
0.2975 SLT $448   0.123  3,638.82   
 ALT $458  $9  0.149 0.026 3,072.65  359.40  
        
0.33475 SLT $448   0.139  3,228.83   
 ALT $458  $9  0.149 0.01 3,072.65  918.06  
        
0.372 SLT $448   0.155  2,901.87   
  ALT $458    0.149   3,072.65  (Dominated) 
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Appendix A4: SLT Effect Failure Sensitivity: Societal Perspective 
SLT 
Effect 
Failure Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr 
C/E 
(ICER) 
-0.004 SLT 448  0.122  3662.3  
 ALT 458 9 0.149 0.026 3072.65 348.69 
        
-0.004 SLT 448  0.123  3657.97  
 ALT 458 9 0.149 0.026 3072.65 350.61 
        
-0.004 SLT 448  0.123  3653.64  
 ALT 458 9 0.149 0.026 3072.65 352.55 
        
-0.003 SLT 448  0.123  3649.33  
 ALT 458 9 0.149 0.026 3072.65 354.51 
        
-0.003 SLT 448  0.123  3645.03  
  ALT 458 9 0.149 0.026 3072.65 356.49 
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Appendix A5: ALT Capital Sensitivity: Societal Perspective 
ALT 
Capital Strategy Cost 
Incr 
Cost Eff Incr Eff C/E 
Incr 
C/E 
(ICER) 
27.42 SLT 448  0.123  3645.03  
 ALT 452 4 0.149 0.026 3036.56 149.15 
        
31.99 SLT 448  0.123  3645.03  
 ALT 455 7 0.149 0.026 3054.6 252.82 
        
36.56 SLT 448  0.123  3645.03  
 ALT 458 9 0.149 0.026 3072.65 356.49 
        
41.13 SLT 448  0.123  3645.03  
 ALT 460 12 0.149 0.026 3090.69 460.16 
        
45.7 SLT 448  0.123  3645.03  
  ALT 463 15 0.149 0.026 3108.74 563.83 
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Appendix A6: SLT Capital Sensitivity: Societal Perspective 
SLT 
Capital Strategy Cost 
Incr 
Cost Eff Incr Eff C/E 
Incr 
C/E 
(ICER) 
23.19 SLT 441  0.123  3585.1  
 ALT 455 14 0.149 0.026 3054.54 536.83 
        
27.055 SLT 445  0.123  3615.06  
 ALT 456 12 0.149 0.026 3063.59 446.66 
        
30.92 SLT 448  0.123  3645.03  
 ALT 458 9 0.149 0.026 3072.65 356.49 
        
34.785 SLT 452  0.123  3674.99  
 ALT 459 7 0.149 0.026 3081.7 266.32 
        
38.65 SLT 456  0.123  3704.96  
  ALT 460 5 0.149 0.026 3090.76 176.15 
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Appendix A7: ALT Effect Success Sensitivity: Ministry Perspective 
ALT 
Effect 
Success Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr C/E 
(ICER) 
0.234 SLT 446  0.122  3644.32  
 ALT 467  0.11  4262.32 (Dominated) 
        
0.273 SLT 446  0.122  3644.32  
 ALT 467 21 0.132 0.009 3540.84 2192.57 
        
0.312 SLT 446  0.122  3644.32  
 ALT 467 21 0.154 0.032 3028.25 649.71 
        
0.351 SLT 446  0.122  3644.32  
 ALT 467 21 0.176 0.054 2645.3 381.36 
        
0.39 SLT 446  0.122  3644.32  
  ALT 467 21 0.199 0.076 2348.34 269.89 
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Appendix A8: ALT Effect Failure Sensitivity: Ministry Perspective 
ALT 
Effect 
Failure Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr 
C/E 
(ICER) 
-0.071 SLT 446  0.122  3644.32  
 ALT 467 21 0.148 0.026 3150.61 800.91 
        
-0.064 SLT 446  0.122  3644.32  
 ALT 467 21 0.151 0.029 3088.22 717.43 
        
-0.057 SLT 446  0.122  3644.32  
 ALT 467 21 0.154 0.032 3028.25 649.71 
        
-0.05 SLT 446  0.122  3644.32  
 ALT 467 21 0.157 0.035 2970.57 593.68 
        
-0.043 SLT 446  0.122  3644.32  
  ALT 467 21 0.16 0.038 2915.04 546.54 
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Appendix A9: SLT Effect Success Sensitivity: Ministry Perspective 
SLT 
Effect 
Success Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr C/E 
(ICER) 
0.228 SLT 446  0.091  4929.13  
 ALT 467 21 0.154 0.064 3028.25 323.83 
        
0.266 SLT 446  0.107  4190.46  
 ALT 467 21 0.154 0.048 3028.25 432.23 
        
0.304 SLT 446  0.122  3644.32  
 ALT 467 21 0.154 0.032 3028.25 649.71 
        
0.342 SLT 446  0.138  3224.13  
 ALT 467 21 0.154 0.016 3028.25 1307.72 
        
0.38 SLT 446  0.154  2890.81  
  ALT 467   0.154   3028.25 (Dominated) 
 
 
 
 
 
 
 
 
 
 
 
 125 
 
Appendix A10: SLT Effect Failure Sensitivity: Ministry Perspective 
SLT Effect 
Failure Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr 
C/E 
(ICER) 
-0.012 SLT 446  0.121  3696.85  
 ALT 467 21 0.154 0.033 3028.25 615.92 
        
-0.01075 SLT 446  0.121  3674.78  
 ALT 467 21 0.154 0.033 3028.25 629.57 
        
-0.0095 SLT 446  0.122  3652.97  
 ALT 467 21 0.154 0.032 3028.25 643.83 
        
-0.00825 SLT 446  0.123  3631.42  
 ALT 467 21 0.154 0.031 3028.25 658.75 
        
-0.007 SLT 446  0.124  3610.12  
  ALT 467 21 0.154 0.031 3028.25 674.37 
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Appendix A11: ALT Capital Sensitivity: Ministry Perspective 
ALT 
Capital Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr 
C/E 
(ICER) 
27.42 SLT 446  0.122  3644.32  
 ALT 462 15 0.154 0.032 2994.32 484.8 
        
31.99 SLT 446  0.122  3644.32  
 ALT 464 18 0.154 0.032 3011.29 567.26 
        
36.56 SLT 446  0.122  3644.32  
 ALT 467 21 0.154 0.032 3028.25 649.71 
        
41.13 SLT 446  0.122  3644.32  
 ALT 470 23 0.154 0.032 3045.21 732.17 
        
45.7 SLT 446  0.122  3644.32  
  ALT 472 26 0.154 0.032 3062.18 814.62 
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Appendix A12: SLT Capital Sensitivity: Ministry Perspective 
SLT 
Capital Strategy Cost 
Incr 
Cost Eff 
Incr 
Eff C/E 
Incr 
C/E 
(ICER) 
23.19 SLT 439  0.122  3583.76  
 ALT 464 25 0.154 0.032 3011.3 801.14 
        
27.055 SLT 443  0.122  3614.04  
 ALT 466 23 0.154 0.032 3019.78 725.43 
        
30.92 SLT 446  0.122  3644.32  
 ALT 467 21 0.154 0.032 3028.25 649.71 
        
34.785 SLT 450  0.122  3674.6  
 ALT 468 18 0.154 0.032 3036.72 574 
        
38.65 SLT 454  0.122  3704.88  
  ALT 470 16 0.154 0.032 3045.2 498.28 
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Appendix B: Different Forms Used in the RCT 
 
Form 0 -Participant Contact Form For the Main Study 
 
Study ID#____________; Initials:_________   DOB:______________  F (    ); M (    ) 
 
 
 
Full Name of the Participant:__________________________ 
 
Hospital chart #____________________________ 
 
What’s the best time to call you?   
 
From_________To _________;  From_________To _________;  
From_________To _________ 
 
Tel # to reach you?  Home phone (                                   ) or cell phone 
(                             ) 
 
Email (if you preferred)? ______________________________________________ 
 
 
If you have someone else to answer the phone or arrange your appointment:   
 
Relationship: ____________________ 
 
Name:_______________________________ 
 
What’s the best time to call him/her?   
 
From________To ________;  From_________To _________;  
From________To ______ 
 
Tel # to reach him/her?  Home phone (                                   ) or cell phone 
(                             ) 
 
Email (if he/she preferred)? ______________________________________________ 
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Form 1-Randomization Form 
 
 
 
Informed Consent    
 
1. Has the participant had the study explained to him/her, signed the Consent Form and 
had a copy given to him/her?  Yes    No 
 
2. Does the participant meet all inclusion and exclusion criteria? Yes    No 
 
 
 
Study Eye (check one) [  ] OD [  ] OS      
 
3. Does the patient agree to be randomized?            Yes    No 
 
4. Web-based Randomization 
 
5. Randomization Number_________________ 
 
6. Treatment group:              Arm 1 (   )                         Arm 2 (  ) 
 
 
 
 
 
 
 
 
 
 
Study 
ID  
# 
Study site 
# 
Study 
Eye  
Patient 
initials 
Today’s 
date (m/d/y) 
 Visit 
 
Staff initials 
     Randomization  
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Form 2-Inclusion and Exclusion Check List 
 
 
 
 
 
 
Inclusion Criteria (yes):  
1. From one of the practices participating in this study (    ). 
2. Older or equal to 18 years of age (    ). 
3. Open angle glaucoma including pigmentary dispersion syndrome and pseudoexfoliation 
syndrome (   ) 
a) Open angle glaucoma (      ) 
b) Pigmentary dispersion syndrome (      ) 
c) Pseudoexfoliation syndrome (      ) 
d) Ocular hypertension (      ) 
4. Previous 360 degree SLT (One time of 360 degree SLT or two 180 SLT on the same eye) 
(        )   
5. Intraocular pressure greater than 16 mm Hg on at least two consecutive occasions separated by 
one month (   ) 
6. Two sighted eyes. Sighted is defined as best corrected visual acuity of 20/200 or better in the 
absence of an advanced VF defect which is defined below (Exclusion Criteria (b)). Two eyes 
of the same patient may not be included in the study. 
7. Willing to participate and sign the consent Form (    ). 
Exclusion Criteria (No): 
1. Any evidence of secondary open angle glaucoma (other than pigmentary and pseudoexfoliation) 
or narrow angle glaucoma (where the anterior trabecular meshwork is not visible 360 degrees). These 
patients would make the study population too heterogeneous (       ).  
2. Previous non laser glaucoma surgery in the eye being considered for treatment as this changes 
the angle architecture too unpredictably to be included (     ). 
3. Intraocular surgery anticipated in the 12 months after treatment  (     ) 
4. Any corneal disease obscuring adequate visualization of the anterior chamber trabecular 
meshwork or reliable applanation tonometry (     ). 
5. Present treatment with topical or systemic steroids or anticipated treatment with systemic steroids 
in the 6 months following treatment because of a high probability condition (such as 
giant cell arteritis or a collagen vascular disease) as steroids themselves have a 
pressure increasing effect in an unpredictable fashion. (     ). 
6. Any previous ALT (      ) 
*IF NO WAS ANSWERED TO ANY INCLUSION CRITERIA, OR YES TO ANY 
EXCLUSION CRITERIA DO NOT ENROLL 
 
 
 
Investigator’s Signature      Date 
 
 
 
Study ID 
# 
Study Site 
 # 
Study 
Eye  
Patient 
initials 
Today’s date 
(m/d/y) 
 Visit 
     Screening 
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Form 3-Baseline Clinical Examination  
(1 of 3 pages) 
 
 
 
 
1. Type of Glaucoma: _____________________ 
2. previous IOP (eg, laser booking date): Measuring date (              )         
1) OD ____  OS ____    2) OD ____  OS ____   3) OD ____  OS ____    
Average IOP on booking date (2 or 3 measures): OD_____OS_____ 
 
Demographics 
 
Date of birth: _____/_____/_____ (dd/mm/yyyy) Gender: [  ] M [  ] F        Eye Colour: 
__________ 
 
Race:  
[  ] Caucasian  
[  ] African 
[  ] Asian 
[  ] Middle East 
[  ] South America 
[  ] Aboriginal  
[  ] or Self Defined ________________ 
 
 
Primary Open Angle Glaucoma Risk Factors: 
(check all that apply) 
[  ] Family History 
[  ] Age (over 60 years) 
[  ] Myopia 
[  ] Elevated IOP (over 21mHg) 
[  ] Ethic background (increased risk if not 
Caucasian) 
[  ] Concomitant Medical Conditions 
(hypertension, diabetes, hypothyroidism) 
[  ] Other(s): 
_______________________________________
Study ID 
# 
Study Site # Study 
Eye 
Patient 
initials 
Today’s date 
(m/d/y) 
 Visit 
     Screening 
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Study Eye:  (check one) [  ] OD [  ] OS      
 
SLT History: 
 
TYPE 
OF 
LASE
R: 
-SLT 
 
DATE 
OF Laser 
EYE(S
) 
-OD 
-OS 
-both 
Degre
es: 
-180 
-360 
-other  
LOCATI
ON:  
-inferior 
-superior  
-nasal 
-temporal 
-other 
Power:  
 
SLT: _. 
_mj  
 
 
Applicat
ion 
(shots): 
 
_ _ _ 
Total 
Energy
= 
(power 
x  
applicat
ions) 
SLT: _ 
_ mj 
 
        
        
        
        
 
Ocular Medical and Surgical History (excluding previous ALT or SLT) 
 
DIAGNOSIS/SURGERY EYE(S) ONSET 
<5YEARS 
5-10 YEARS 
>10YEARS 
ONGOING OR 
RESOLVED 
    
    
    
    
 
Form3 (Baseline, 2/3) 
 
Non-Ocular Medical and Surgical History: 
DIAGNOSIS/SURGERY ONSET (<5 
YEARS;  
5-10 YEARS; >10 
YEARS) 
ONGOING OR 
RESOLVED 
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Intraocular Pressure (IOP) 
METHOD OF 
MEASUREMENT 
TIME IOP (mmHg) 
⁪ Goldman Applanation 
Tonometry 
IOP: take two measurements 
& average them if the diff. is 
< 2 mm Hg. 
-If the difference ≥3 mm Hg, 
take 3 measurements and take 
the median as the value. 
____:____hrs 
(24 hour clock) 
 
1. OD ____  OS ____                  
2. OD ____  OS ____ 
3. OD ____  OS ____ 
 
Average IOP  
OD ____  OS ____ 
 
Target IOP for this 
Patient?_____________________________________________________________ 
 
 
Signature of Mire Reader       Date 
 
 
Signature of Dial reader        Date 
 
Central Corneal Thickness (CCT): 
METHOD OF 
MEASUREMENT 
TIME CCT (µM) 
 
 
⁪ Ultrasound Pachymetry 
 
 
 
___:___ hrs 
(24 hour clock) 
 
OD ______ µm 
 
OS ______ µm 
 
 
Signature of Person Performing CCT      Date 
Form3 (Baseline, 3/3) 
Best-Corrected Visual Acuity (BCVA): 
METHOD OF 
MEASUREMENT 
TIME VISUAL ACUITY 
 
 
⁪ Snellen 
 
 
 
___:___ hrs 
(24 hour clock) 
 
OD ___________ 
 
OS ___________ 
 
* For consistency please use the same chart in the same room, using the same lighting throughout the trial.  
 
Signature of Person Performing BCVA      Date 
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SCORING RIGHT EYE (OD) LEFT EYE (OS) 
Modified Shaffer 
 
Closed 
Schwalbe’s Line 
Trabecular Meshwork 
Scleral Spur  
Ciliary Body Band                                   
Gonioscopy (with gonio 
lens) 
  
Grade 0     ⁪     
Grade 1     ⁪ 
Grade 2     ⁪ 
Grade 3     ⁪ 
Grade 4     ⁪ 
 
Gonioscopy (with gonio 
lens) 
 
Grade 0     ⁪  
Grade 1     ⁪ 
Grade 2     ⁪ 
Grade 3     ⁪ 
Grade 4     ⁪ 
 
 
 
None 
Light  
Medium 
Dark Brown 
Almost Black                          
Trabecular Meshwork 
(Angle) Pigmentation 
 
Grade 0     ⁪ 
Grade 1     ⁪ 
Grade 2     ⁪ 
Grade 3     ⁪ 
Grade 4     ⁪    
 
Trabecular Meshwork 
(Angle) Pigmentation 
 
Grade 0     ⁪ 
Grade 1     ⁪ 
Grade 2     ⁪ 
Grade 3     ⁪ 
Grade 4     ⁪ 
 
 
PAS is absent or 
present 
Peripheral Anterior 
Synechiae 
 
Absent     ⁪ 
Present    ⁪ 
 
Peripheral Anterior 
Synechiae 
 
Absent     ⁪ 
Present    ⁪ 
 Cup to Disc Ratio 
 
0.__ 
Cup to Disc Ratio 
 
0.__ 
Cells Scoring:  
0=0 cells; +0.5=1-5 cells 
(trace); +1=6-15 cells; 
+2=16-25 cells; +3=26-50 
cells; +4=>50cells 
Flare Scoring: 
0=None; +1=Faint; 
+2=Moderate; 
+3=Marked; +4= Intense 
Anterior Chamber 
Inflammation 
 
Cells _____ 
Flare _____ 
Anterior Chamber 
Inflammation 
 
Cells _____ 
Flare _____ 
 
 
 
Signature of Person Performing Ophthalmic Examination     Date 
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Form 4-Laser Treatment Log Record  
(page 1 of 2) 
 
 
Study Eye:  (check one) [  ] OD [  ] OS  
     
Prior to Laser Check IOP, BCVA and AC for inflammation 
 
Intraocular Pressure (IOP): or Not Done ⁪ (Screening and Treatment Combined) 
 
METHOD OF 
MEASUREMENT 
TIME IOP (MMHG) Baseline IOP rule 
⁪ Goldman 
Applanation 
Tonometry 
To measure IOP:  
-Take two 
measurements and 
average them if the 
difference is within 2 
mm Hg. 
-If the difference is 
greater than 3 mm Hg, 
take 3 measurements 
and take the median as 
the value. 
 
____:____hrs 
(24 hour 
clock) 
 
1. OD ____  
OS ____                  
 
2. OD ____  
OS ____ 
 
3. OD ____  
OS ____ 
 
Average IOP 
OD ____  OS ____ 
Average of IOP on 
booking date  (Avg 
OD____ OS_____) 
and laser date (if 
different date from the 
baseline measurement 
date) (Avg OD____ 
OS_____) 
 
Baseline IOP:  
OD____ OS_____ 
 
* the computer will do 
the calculation of  
Baseline IOP, you may 
verify it, if you have 
any doubt,  please let 
Francie know . 
 
 
Signature of Mire Reader       Date 
 
 
Signature of Dial reader      
 
 
 
 
 
 
 
 
Study 
ID  
# 
Study Site  
# 
Study 
Eye 
Patient 
initials 
Today’s 
date 
(m/d/y) 
Visit 
Study arm 
1 or 2  
     Laser treatment  
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Best-Corrected Visual Acuity (BCVA): or Not Done ⁪ (Screening and Treatment 
Combined) 
 
METHOD OF 
MEASUREMENT 
TIME VISUAL ACUITY 
 
 
⁪ Snellen  
 
 
 
___:___ hrs 
(24 hour clock) 
 
OD ___________ 
 
OS ___________ 
 
*If three letters or more are read correctly on that line, capture that line on the source document (ie; 
if the patient reads all but 2 letters correctly on the 20/20 line, you will still record 20/20 as the visual 
acuity) 
*As per inclusion (e): Two sighted eyes. Sighted is defined as best corrected visual acuity of 20/200 or 
better 
*If the patient cannot read 20/400 or better, check for CF, HM, LP 
* For consistency please use the same chart in the same room, using the same lighting throughout the 
trial, if possible 
 
 
Signature of Person Performing BCVA      Date 
 
 
Form 4-Laser Treatment Log Record (page 2 of 2) 
 
 
 
CELLS SCORING:  
0=0 CELLS; +0.5=1-5 
CELLS (TRACE); +1=6-
15 CELLS; +2=16-25 
CELLS; +3=26-50 
CELLS; +4=>50CELLS 
FLARE SCORING: 
0=NONE; +1=FAINT; 
+2=MODERATE; 
+3=MARKED; +4= 
INTENSE 
ANTERIOR CHAMBER 
INFLAMMATION (OD) 
 
CELLS _____ 
FLARE _____ 
ANTERIOR CHAMBER 
INFLAMMATION 
(OS) 
 
CELLS _____ 
FLARE _____ 
 
 
 
Signature of Person Performing AC Examination     Date 
Study 
ID  
# 
Study Site  
# 
Study 
Eye 
Patient 
initials 
Today’s 
date 
(m/d/y) 
Visit 
Study arm 
1 or 2  
     Laser treatment  
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Laser treatment: 
 
Time: _ 
_hour_ 
_min 
ALT SLT 
 Protocol (p) Actual Protocol Actual 
Location ⁪Inferior 180 (p) 
⁪superior 180 
⁪nasal 180 
⁪temporal 180 
 ⁪Inferior 180 
(p) 
⁪superior 180 
⁪nasal 180 
⁪temporal 180 
 
Applications 50    50  
Spot size 50 uM   400 uM  
Duration 0.1 sec   3 nsec  
Power range 400-800  mW   0.5 -1.4 mJ  
Total energy 
(Application 
x power) 
_ _application  x 
___mW /1000 
_ _._ _ _W __applications  
x 
_._mJ 
_ _ ._ mJ 
Total Energy 
Level from 
the 
Machine? 
    
Brimonidine- 
post laser 
1 drop  1 drop   
 
 
 
 
Signature of Person Performing Laser      Date 
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Form 5 -Follow-Up Examinations (for 1 h, 1wk, 1 /3/6 mon) 
(page 1 of 2) 
 
 
Any changes to concomitant medications?  Yes⁪ (document on concomitant 
medication form) No⁪ 
Any Adverse Events to report?  Yes ⁪ (document on Adverse Event Log) No⁪ 
 
Intraocular Pressure (IOP):  
 
METHOD OF 
MEASUREMENT 
TIME IOP (MMHG) 
⁪ Goldman Applanation 
Tonometry 
To measure IOP:  
-Take two measurements and 
average them if the difference is 
within 2 mm Hg. 
-If the difference is greater than 
3 mm Hg, take 3 measurements 
and take the median as the value. 
 
 
____:____hrs 
(24 hour clock) 
1. OD ____  OS 
____                  
 
2. OD ____  OS 
____ 
 
3. OD ____  OS 
____ 
 
Average IOP 
OD ____  OS ____ 
 
 
*≥5mmHg increase in IOP is considered an Adverse Event, please document on 
Adverse Event Log. 
Medication given for elevated IOP? Yes⁪ (document on concomitant medication 
form) No⁪ 
 
 
 
Signature of Mire Reader       Date 
 
 
Signature of Dial reader      
 
 
If additional IOP measurements taken, please document below. 
Study 
ID  
# 
Study Site  
# 
Study 
Eye 
Patient 
initials 
Today’s 
date 
(m/d/y) 
Visit 
(1H/1W/1M/3M/6M) 
Study 
arm 1 or 2  
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If additional medication given for elevated IOP, please document on concomitant 
medication form. 
 
 
Time: ___:___ hrs OD ___mmHg 
   OS ___mmHg 
 
Time: ___:___ hrs OD ___mmHg 
   OS ___mmHg 
 
Time: ___:___ hrs OD ___mmHg 
   OS ___mmHg 
 
 
Form 5 -Follow-Up Examinations (for 1 h,  1wk,  1 /3/6 mon)  
(page 2 of2) 
 
 
 
 
Best-Corrected Visual Acuity (BCVA):  
 
METHOD OF 
MEASUREMENT 
TIME VISUAL ACUITY 
 
 
⁪ Snellen 
 
 
 
___:___ hrs 
(24 hour clock) 
 
OD ___________ 
 
OS ___________ 
 
*If three letters or more are read correctly on that line, capture that line on the source document (ie; 
if the patient reads all but 2 letters correctly on the 20/20 line, you will still record 20/20 as the visual 
acuity) 
*As per inclusion (e): Two sighted eyes. Sighted is defined as best corrected visual acuity of 20/200 or 
better 
*If the patient cannot read 20/400 or better, check for CF, HM, LP 
* For consistency please use the same chart in the same room, using the same lighting throughout the 
trial, if possible 
 
 
Signature of Person Performing BCVA      Date 
 
 
 
 
Study 
ID  
# 
Study Site  
# 
Study 
Eye 
Patient 
initials 
Today’s 
date 
(m/d/y) 
Visit 
(1H/1W/1M/3M/6M) 
Study 
arm 1 or 2  
       
 140 
 
 
 
CELLS SCORING:  
0=0 CELLS; +0.5=1-5 
CELLS (TRACE); +1=6-
15 CELLS; +2=16-25 
CELLS; +3=26-50 
CELLS; +4=>50CELLS 
FLARE SCORING: 
0=NONE; +1=FAINT; 
+2=MODERATE; 
+3=MARKED; +4= 
INTENSE 
ANTERIOR CHAMBER 
INFLAMMATION 
(OD) 
 
CELLS _____ 
 
FLARE _____ 
ANTERIOR CHAMBER 
INFLAMMATION 
(OS) 
 
CELLS _____ 
 
FLARE _____ 
 
 
 
Signature of Person Performing  Examination     Date 
 
Other findings by 
Investigator:_____________________________________________________________
________________________________________________________________________
________________________________________ Course/Complications: (check all that 
apply) 
 [  ] Anterior Chamber Reaction 3+ or greater 
 [  ] Pain or Discomfort 
 [  ] Blurred Vision 
 [  ] IOP Spike (increase of 5mmHg or more) indicate increase __mmHg 
 [  ] Persistent IOP Elevation 
 [  ] Peripheral Anterior Synechiae 
 [  ] Corneal cloudiness 
 [  ] Scarring 
 [  ] Others: ________________________________________________________ 
            [  ] None 
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Appendix C: Recalculation of Power of the Study for Reduced Sample Size 
As we have an active control group (ALT) and a comparator group (SLT), the 
total sample size (for both active control and comparator group) would be: 
                                  2(N) = 2{2v2 (Zα+Zß)2 /d2}  
   When 2(N) = 91 
   v2 = 52 
   Zα = 1.96 
   d2 = 32 
  Then, Zß = 0.9 
When Zß = 0.9, the power of the study = 81% 
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